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ABSTRACT
Polycylic aromatic hydrocarbons (PAHs) are a group of chemically-related
compounds with a well-established body of evidence of adverse human health impacts.
Additionally, there is a growing area of research on the health outcomes following PAH
exposure via air pollution, specifically with chronic obstructive pulmonary disorder
(COPD) and lung cancer. The purpose of this dissertation was to investigate the strength
of associations among PAHs, COPD, and lung cancer from ambient (outdoor) air
pollution. The first objective was to determine if there is a potential environmental link
among PAHs, COPD, and lung cancer occurrence among nonsmokers using data from
the National Health and Nutrition Examination Survey (NHANES). The second objective
was to test the hypothesis that a significant association exists among PAHs, COPD, and
lung cancer deaths in South Carolina (SC) using the National Air Toxics Assessment
(NATA) models developed by the Environmental Protection Agency (EPA). The third
and final objective of this research was to utilize the models developed in the previous
objective and apply it to a large metropolitan context to determine if the same or similar
associations with COPD and lung cancer deaths were observed. New York City was
selected as the jurisdiction for this section of the research due to its context of a probable
interface with a dense population and a variety of known air pollution sources i.e. the port
of NY/NJ.
For the first objective, PAHs were not statistically significant (p=0.4828) in their
association with COPD occurrence among non-smoking respondents after adjusting
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for known confounders i.e. age, secondhand smoke exposure, former smokers, BMI, etc.
The results investigating the strength of association between PAHs and lung cancer
among nonsmokers were unreliable due to the small sample size of lung cancer
respondents (n=37) in the NHANES dataset and are not included.
For the second objective, PAHs were significantly associated with COPD deaths
(p=0.0094 to p<0.0001) at the census tract level in SC, while adjusting for known
confounders i.e. demographic compositions, smoking prevalence, obesity prevalence,
primary care provider rates, etc. Additionally, the point estimates for PAHs were
indicated in the positive direction for each COPD model. Interpreting the rate ratio
observed from the respective model estimates for PAHs (β=0.1352 to β=0.243) would be
as follows: for every log unit increase of PAHs in SC, the rate of deaths due to COPD
increased by 14% to 24% across all models. The lung cancer death model for SC did not
reveal statistically significant results for PAHs (p=0.0997 to p=0.7776).
The results for the third objective for New York City were mixed. For both COPD
and lung cancer death models, there were statistically significant associations with PAHs
at the census tract level (p<0.0001to p=0.04), however not across all years. Furthermore,
point estimates for each set of models were also indicated in both positive and negative
directions.
In conclusion, taking into account each of the confounders included in the
analysis for the COPD death model in SC specifically, there are implications for air
pollution remediation across the state. Additional study is warranted investigating a
morbidity model using data such as hospitalizations from acute exacerbations of COPD
(as well as lung cancer or other respiratory-related illnesses, i.e. asthma) and
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investigating their associations with PAHs at the census tract level. A death model
includes a longer period of time between dose and response which could be mitigated
with a morbidity model. Next, other biomarkers for air pollutants, i.e. particulate matter
<2.5um (PM2.5), are worthy of investigation among the NHANES laboratory sample to
test for significance with COPD, lung cancer and other known adverse health outcomes
from pollution. Finally, investigation into environmental justice issues are warranted in
regards to more localized analyses of PAH exposure and adverse health outcomes among
populations who reside most proximate to known pollution sources i.e. the neck
communities of Charleston, SC.
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CHAPTER 1
INTRODUCTION
Overview
PAHs are a group of chemical compounds that are mostly colorless and made up
of several hundred related compounds of various sizes and toxicity. They are
environmentally ubiquitous and identified as persistent organic pollutants (POPs) with
documented bio-accumulation in numerous flora and fauna (Nadal et al., 2015). Sources
of PAHs include motor vehicle exhaust, tobacco smoke, coal production, biomass
burning, or from any context in which organic carbon is being combusted. PAHs bound
to particulate matter (PM) are of increased importance for ambient (outdoor) air quality,
especially in regards to the adverse health outcomes linked to PM (Hayakawa et al.,
2017). Additionally, PAHs were one of the first atmospheric pollutants labelled as a
suspected human carcinogen (Kim et al. 2013).
Among the associations of PAHs, COPD, and lung cancer, exists is a budding
area of research when it comes to PAH exposures and direct COPD outcomes. While, the
scientific literature assessing PAHs and lung cancer is well established (Moorthy et al.,
2015). Additionally, few studies have been devoted to the relationship of all three in the
context of ambient air pollution and its adverse health effects (Marino et al., 2015; Pauk
et al., 2013).
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Globally, COPD kills over 3 million people each year (Rabe & Watz, 2017) and
was the third leading cause of death in 2010 (Burney et al., 2015). According to the
World Health Organization (WHO), COPD is predicted to be the fifth leading cause of
disability in the world by 2020 (Viegi et al., 2006). Individuals with COPD have twice
the risk of developing cancer in the lung (Young et al., 2015), where lung cancer is
frequently diagnosed as a comorbidity (Schroedl & Kalhan, 2012). The links between
smoking, lung cancer, and COPD are highly documented, however recent studies have
demonstrated that some 25 percent of COPD patients are non-smokers and its burden
among non-smokers is likely underestimated (Zeng et al., 2012). Furthermore, estimates
of lung cancer deaths in the U.S. among never smokers ranged from 16,000 to 24,000,
equaling about 10 to 15 percent of total lung cancer deaths (Samet et al., 2009).
Both acute and chronic exposures to air pollution have been associated with
COPD death and incidence around the world at levels below air quality guidelines (Liu et
al., 2016). Impacts from air pollution on COPD are numerous in the scientific literature
and have been specifically documented in their association with PM, however a small but
growing number of them have isolated PAHs in their respective mechanisms for
pathogenesis, and even fewer have isolated how the additional presence of lung cancer
adds to the overall pathogenic potential (Li et al., 2016, Hamra et al., 2014). The precise
elements of PM and their associated pathogenesis with COPD were inconclusive prior to
the work of (Yang et al., 2017a) where the link between PAHs and COPD is of increasing
importance for investigation vis-a-vis Yang’s proposed biological mechanism and
pathway. This mechanism and pathway provide promising evidence for the etiology and
pathogenesis of COPD from PAH exposure. Since this mechanism has significant overlap
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with lung cancer pathogenesis, its comorbidity with COPD is of increasing interest as
well.
Specifically, the impact to public health from PAHs in South Carolina is a salient
investigation as the city of Charleston, the SC Port Authority, and other relevant
stakeholders across the state, plan and implement the expansion of the city’s harbor.
Activities for expansion include dredging to deepen the harbor for greater capacity to
handle massive container ships traveling from the recently expanded Panama Canal as
well as a new container terminal in the former Navy base in North Charleston. Dredging
was set to begin late 2017 and completed by 2020 when the container terminal is set to
open. Impact assessments and preliminary evaluations have been completed i.e.
Kimbrough et al. (2015), however an investigation into how PAHs could have both a
short and long term impact on health in an urban context like Charleston will offer
greater understanding of the burden to public health with a future that has significant
increases to air pollution sources.

Specific Aims
The overall goal of this research was to investigate PAH concentrations from
ambient air pollution and associations with COPD morbidity and mortality as well as
lung cancer morbidity and mortality. The focus of the literature review was to provide a
proof of concept and an evidence base for COPD and lung cancer associations from
PAHs alone. Additional health outcomes (i.e. heart disease and stroke) could be
addressed to understand the extent of the public health burden caused by PAHs, however
this is beyond the scope of the study.
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The literature review focused on PAHs, their emission sources, known
transportation routes and fate, and various health impacts. Additionally, a review of the
current literature was provided on COPD burden, pathogenesis following PAH exposure,
and relevant environmental-epidemiological studies. Finally, the primary findings from
the literature of lung cancer comorbidity with COPD from outdoor air pollution exposure
were summarized in addition to identifying the similarities of their etiopathogenesis.
Chapter two is a cross-sectional analysis of the association of PAH metabolites
and the presence of COPD and lung cancer using National Health and Nutrition
Examination Survey (NHANES) laboratory, examination, and questionnaire data. The
analytical approach taken was modeled after Shiue (2016) where emphysema, chronic
bronchitis, and asthma were measured in strength of association with PAH metabolites
using NHANES data. Additionally, the work of Tilert et al. (2013) used spirometry
readings from NHANES to determine COPD diagnoses as well as a national COPD
prevalence estimate. Lastly, a study by Mannino et al., (2003) investigated the association
between low lung function (spirometry-confirmed COPD) alongside lung cancer
incidence using NHANES data as well. Essentially, the primary elements mentioned in
the three studies above (PAH associations, spirometry-confirmed COPD, and lung cancer
comorbidity) have not been studied altogether with NHANES data. Thus, PAH
associations with spirometry-confirmed COPD, along with an investigation into
associations of lung cancer, provide the rationale for chapter two’s contribution to the
environmental epidemiological literature for PAHs.
The primary goal of chapter two was to determine whether there is an association
of PAH levels and spirometry-confirmed COPD as well as lung cancer occurrence from a
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national perspective as a means to isolate a potential environmental etiology distinct from
tobacco smoke. Null hypothesis: There is no significant association between PAH levels
and spirometry-confirmed COPD and lung cancer co-occurrence among non-smokers.
To investigate this association further, estimates of COPD-lung cancer mortality
attributable to PAHs in ambient air pollution were assessed. Chapters three and four
investigated outdoor air quality in two U.S. jurisdictions (the state of South Carolina and
New York City (NYC)) and the corresponding associations with COPD and lung cancer
mortality. Investigating South Carolina as a whole provides a logical step following
chapter two’s NHANES analysis to provide a state-based study of PAHs and COPD-lung
cancer associations. The rationale for choosing NYC in chapter four’s study was the
increased amount of transportation and corresponding likelihood of air pollution exposure
that its port provides. The contribution of motor vehicle exhaust from land and water
transport in an area that is a significant population center delineates a study area with a
probable interface between humans and air pollution, specifically PAHs (Rosenbaum et
al., 2011; Sharma, 2006; Smailys et al., 2007). Additionally, the expansion of the port in
Charleston made this a worthy study area for improved means of understanding the
projected burden to public health.
Thus, chapter three was a state-wide perspective of the health burden from PAHs
in outdoor air using SC as the study area. Mortality data for COPD and lung cancer were
acquired from the SC Department of Health and Environmental Control’s Office of Vital
Statistics (DHEC VS) in five year aggregates between 2002 and 2014. Demographic and
other relevant confounding variables were acquired from various sources. The full list of
covariates from the DHEC VS dataset (as well as additional socio-economic and
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environmental variables) is included in chapter three’s methods. Also, included in the
methods is the rationale for the identified covariates with supporting literature. Air
quality data for PAH exposure concentrations was acquired from the U.S. Environmental
Protection Agency’s (EPA) National Air Toxics Assessment (NATA) dataset that
provides census track level PAH exposure estimates for years 2002, 2005 and 2014. A
Poisson regression analysis was carried out to develop two predictive models that
estimated 1) the proportion of COPD deaths given the amount of PAH exposure
concentrations in each census tract and 2) the proportion of lung cancer deaths given the
amount of PAH exposure concentrations in each census tract. Null hypothesis: There is
no significant association between NATA-derived PAH exposure concentrations and
mortality from COPD and lung cancer at the census tract level in the state of South
Carolina.
Similarly, chapter four investigated the outdoor air quality of PAHs in NYC and
its associations with COPD and lung cancer mortality. The model developed in chapter
three was applied in this urban setting to determine whether a significant burden exists in
the context of increased exposures due to the area’s dense population and proximity to
known point and non-point sources of PAH pollution such as in and around the port. The
same dataset for air quality from NATA was used to assess exposures at the census tract
level as in chapter three for the same years. Census tracts included in the analysis were
those contained in the five counties that make up New York City – Bronx, Kings, New
York, Queens, and Richmond counties. Deaths from COPD and lung cancer were
acquired from New York City’s Vital Statistics Office for the corresponding years of
available NATA data in five year aggregates between 2002 and 2014. Tests for
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significance and association were analyzed using a Poisson regression analysis. Models
were explored to determine the strength of associations to predict the proportion of deaths
from COPD and lung cancer given the amount of PAH exposure concentrations in each
census tract of NYC while adjusting for known confounders. Null hypothesis: There is
no significant association between NATA-derived PAH exposure concentrations and
mortality from COPD and lung cancer at the census tract level in NYC.

Literature Review
PAHs – Overview, Sources, Transport, and Fate
Incomplete combustion of organic materials is characterized by an orange flame,
while its counterpart of complete combustion is blue. Polycyclic aromatic hydrocarbons
(PAHs) are organic pollutants resulting from incomplete organic carbon combustion.
PAHs are arenes (most commonly occurring as benzene rings) and termed aromatic
compounds since they consist of two or more fused rings (in addition to their aromatic
quality). They exist in both gaseous and particle phases according to their volatility.
Gaseous PAHs have a light molecular weight and have two or three aromatic rings, while
those in the particle phase have a high molecular weight and consist of five or more rings.
PAHs having three or four rings can occur in both phases (Abdel-Shafy & Mansour,
2016). Within the various structural formations of PAHs, additional classifications can be
carried out based on their melting point, vapor pressure, and water solubility.
PAH sources are petrogenic (hydrocarbons associated with petroleum), pyrogenic
(hydrocarbons associated with combustion of petroleum, wood, coal, tobacco, etc.), and
biologic. Primary sources for PAHs typically result from anthropogenic activity such as
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tobacco smoke, motor vehicle exhaust, residential heating, coal gasification and
liquefying plants, carbon black, coal-tar pitch and asphalt production, coke and aluminum
production, as well as catalytic cracking towers and related activities in petroleum
refineries (Abdel-Shafy & Mansour, 2016). Natural or non-anthropogenic sources for
PAHs are formed during various biological processes and in other combustion contexts
such as wildfires and volcanic activity.
Lee and Vu (2010) divide PAH emissions into four classes: stationary sources,
mobile emissions, agricultural activities, and natural sources. Stationary sources include
both domestic and industrial emissions including biomass burning in the home for
cooking and heating, as well as gas, oil, and coal burning through much of the
anthropogenic activities listed above. Additional industrial sources include pyrolysis of
municipal, medical, and industrial wastes, among other organic-waste materials i.e.
garbage, scrap tires, etc. (Chen et al., 2007, Lee, et al., 2003). Mobile emissions are
summarized by those occurring from any vehicle including automobiles (and other motor
vehicles i.e. motorbikes), trains, airplanes, and ships. Agricultural sources for PAH
emissions are primarily those resulting from biomass burning such as burning
brushwood, straw, etc. Finally, natural sources include burning from wildfires caused by
lightning strikes, volcanic eruptions, and decaying organic matter.
Long range PAH transmission through the environment takes place primarily
through atmospheric transport. Various processes disperse PAHs through the air and
move them through terrestrial and aquatic environments (Abdel-Shafy & Mansour,
2016). PAHs are affected by photodegradation as well as other forms of degradation as
they can react with ambient pollutants such as ozone (O3), sulfur dioxide (SOX), and
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nitrogen oxides (NOX), ultimately impacting their fate and condition (Lee and Vu, 2010).
Additionally, the fate and transport of PAHs is determined by their particle and gaseous
phases as they are partitioned in the atmosphere. This controls the exposure pathway that
PAHs can enter the human body, among other biota. PAHs are removed from the
atmosphere through wet and dry deposition processes, which is again, based on their
original particle or gaseous phases. In this regard, atmospheric deposition is a primary
source of PAH concentration in soil (Abdel-Shafy & Mansour, 2016). Since PAH
persistence in the environment is moderate, bio-accumulation has been documented in
fish, shellfish, and terrestrial vertebrates (Beyer et al., 2010).
PAHs have been studied significantly as a component of air pollution (Fawole et
al., 2016, Lewtas, 2007, Baek et al., 1991). For example, PAHs sorbed to solid particles
in the air was assessed by Huzlik et al. (2017) to determine their emission/pollution
sources. The approach to analyzing PAH origins was based on several criteria. These
included: the size and shape of compounds captured as solid particles; assessment of the
physical and chemical properties of the captured solids; statistical methods whereby air
pollutants were modeled based on their concentrations and sources and; measurement of
certain characteristics in the chemical composition of contaminants attached to solid
particles. Their findings revealed a significant seasonality to PAH concentrations in the
air. Specifically, it was suggested that the use of heating stoves that burn organic fuels in
the winter as well as atmospheric transport were the primary contributors to the PAH
concentrations that were under investigation according to their specific ratios.
Conversely, other PAH concentration ratios were observed during the summer months
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where it was concluded that atmospheric transport alone was the contributor to air
pollution.
Tanaka & Sakata (2002) sought to clarify the effect of photooxidation on two
primary PAHs, benzo[a]pyrene (BaP), benzo[e]pyrene (BeP), and their respective
isomers. According to the study, BaP and BeP had different photooxidation rates than
their isomers. The results revealed that BaP concentrations were reduced by
photooxidation while the delta(13)C isomer of BaP increased during ultraviolet
irradiation experiments. Additionally, BeP was not photooxidized and had no change in
its respective isomer. According to the results, the ratios of BaP/BeP with their respective
isomers had similar levels during the winter than they had during the summer, in spite of
photooxidation being less likely to occur during the colder and darker months. Thus, the
findings support the explanation that BaP was photooxidized during long-range transport
as it traveled from its sources from the Asian continent prior to reaching the islands of
Japan, which was the study area.
Numerous studies and several reviews have assessed the transport and fate of
PAHs in aquatic environments (Reynaud & Deschaux, 2006; Cerniglia, 1992; Zhang et
al., 2015). A riverine example, Boonyatumanond et al. (2006) collected sediment samples
from various waterways in Thailand and analyzed them for PAH concentrations. They
found concentrations rooted in both petrogenic and pyrogenic sources. Most petrogenic
profiles of PAHs found were diffuse throughout the country, suggesting a single source
of automobile contribution. Low levels of pyrogenic PAHs were frequently recorded in
coastal areas of the Chao Phyara River, suggesting atmospheric transport throughout the
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country. Mixed profiles of petro-pyrogenic PAHs were recorded as well in middle and
lower levels of the Phyara River, its mouth, and in the upper Gulf of Thailand.
In another aquatic study, Feng et al. (2007) analyzed PAH concentrations from
the Wuhan region of the Yangtze River in China to determine potential sources as well as
eco-toxicological effects. They found the average PAH concentration in suspended
particulate matter (SPM) in the water was significantly higher than in the sediment. PAH
profiles and their specific ratios indicated their primary source in the Yangtze was from
coal and wood burning atmospheric deposition. PAH concentrations were above drinking
water standards, however the study concluded that acute biologic effects were not caused
by PAHs in the sedimentary environment of the Yangtze, although they may pose a
potential toxic effect from chronic exposure.
In addition to riverine systems, aquatic transport of PAHs is relevant with
stormwater. Nielsen et al. (2015) assessed PAH concentrations in stormwater from
highway runoff. Their rationale, as urbanization and anthropogenic activities increase,
urban stormwater has turned into a pollution source for receiving waters. A primary
challenge for stormwater pollution management is pollutants are typically combined with
colloidal particles which are not effectively removed according to current pollution
remedial solutions. The results from Nielsen et al. (2015) support this growing area of
concern with findings such as 45 percent of the PAHs they analyzed in stormwater were
present in colloidal and dissolved fractions, further demonstrating the persistent and
ubiquitous quality of PAHs as pollutants.
Highlighting other areas of PAH fate and transport throughout the environment
include the pathway of food ingestion. Zelinkova & Wenzl (2015) reviewed
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epidemiological findings of the occurrence of PAHs in food and the potential threat to
human health from exposure to PAHs from ingestion. Contamination of food from PAHs
can occur through the air, soil, water, as well as during cooking and food processing. One
of the findings presented was a study by the European Scientific Committee on Food
(SCF) in 2002 investigating the total intake of PAHs from food versus other pathways of
exposure. They determined food ingestion was the primary source of PAH intake in their
area of study, which corresponds to the International Association of Research on
Cancer’s (IARC) major findings of carcinogenic potential of PAHs from ingestion,
especially BaP (WHO & IARC, 2005).
Health Effects of PAHs
Priority PAHs were determined by the U.S. Environmental Protection Agency
(EPA) in 1976 to analyze the risks of drinking water on human health. A list of 16
priority PAHs was developed, leading to a significant body of environmental studies on
PAH impact and human health (Andersson & Achten, 2015; Keith, 2015). Appendix A
lists the 16 priority PAHs developed by the EPA. The following section will summarize
the primary findings of the health impacts of PAHs.
The U.S. Department of Health and Human Services’ Agency for Toxic
Substances and Disease Registry (ATSDR) released a public statement in 1995 providing
an overview of the known health effects of PAHs (ATSDR, 1995b). ATSDR summarized
the known animal studies demonstrating carcinogenic effects of PAHs as well as the
human studies leading to cancer. The primary exposure routes of the identified studies
were inhalation and dermal, which provides a counter-perspective to the SCF findings
above, albeit one that was released almost seven years prior. Additional findings revealed
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in the animal studies only, showed harmful effects in immune response and effects to the
skin and body fluids from both short and long-term exposures (ATSDR, 1995b). These
animal studies provided the biological basis for adverse health effects of PAHs in regards
to skin and immune responses in humans. Additional human studies in these areas have
followed and are mentioned below.
A seminal review of the carcinogenic effects from PAHs was released by IARC in
their 2010 monograph evaluating the human cancer risks from PAH exposure. Their
overall evaluation of carcinogenic potential and strength of evidence for human
carcinogenicity can be found elsewhere (World Health Organization, International
Agency for Research on Cancer, 2010). A significant body of epidemiological findings
was identified by IARC detailing sufficient evidence especially for occupational
exposures in vocations such as coal gasification, coke production, coal-tar distillation,
and chimney sweeps, among several others. Documented routes of exposure were
primarily inhalation and dermal.
A review of the specific carcinogenic effects of PAHs on the lung was provided
by Moorthy et al. (2015). Specifically, lung cancer frequently results from excessive
PAH exposure and is the leading cause of death from cancer for both men and women in
the United States (Horn et al., 2012). With this focus, the review documented various
pathways of carcinogenesis including induction of multiple metabolic enzymes via the
aryl hydrocarbon receptor (AhR). After humans are exposed to PAHs, they can be
metabolized and formed into carcinogens that lead to DNA adducts which can result in
mutations, gene alteration, and tumor formation. These effects occur in certain
demographics more than others, highlighting various susceptibilities among different
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races/ethnicities, genders, and age groups (Timofeeva et al., 2010; Dong et al., 2012;
Spitz et al., 2013).
In addition to carcinogenic effects, other chronic and acute health effects can
result from PAH exposure. Short term health impacts include eye and skin irritation,
nausea and vomiting, as well as impaired lung function that can lead to effects on
asthmatics and thrombosis (blood clots) in people with coronary heart disease (Unwin et
al., 2006). Long term health effects have been demonstrated in a variety of studies with
the most prominent findings focusing on occupational exposure (Kim et al., 2013). This
is of interest for determining chronic health impacts of PAHs beyond cancer alone.
ATSDR’s toxicological profile identifies PAHs as probable inducers of cataracts and can
cause kidney and liver damage (ATSDR, 1995a). The inflammatory response to PAHs
can lead to other forms of cardiopulmonary mortality over time as well (Kuo et al., 2003).
As mentioned above, COPD effects from PAH exposure is a growing area of
research. A significant body of this research has its origin in China as COPD is in its top
five leading causes of death in addition to the increased exposure to air pollution present
throughout the country (Fang et al., 2011). Although the essential components of PM2.5
in COPD pathogenesis were previously inconclusive, Yang et al. (2017) provide a novel
biological basis for their association. The authors’ proposed biological mechanism and
pathway utilized PAHs bound to PM2.5, showing they were induced by severe oxidative
stress leading to DNA damage, inflammatory response, and decreased gene expression.
By this mechanism, risks of COPD were documented during haze events in China.
Furthermore, it was determined the PAH component of PM2.5 extracts were the specific
cause of these effects through the AhR pathway.
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Finally, teratogenic effects have been documented following PAH exposure.
Animal studies providing the basis for more recent investigation in humans on
embryotoxic effects include Kristensen et al., (1995) and Wassenberg & Di Giulio
(2004). Human studies such as those utilizing data from the U.S. Center for Children’s
Environmental Health (CCEH), demonstrated the linkage between adverse health
outcomes (i.e. low birthweight, preterm births, and delayed childhood development) with
prenatal exposure to PAHs (Perera et al., 2005). Additional childhood-related outcomes
from prenatal PAH exposure include associations with asthma, behavioral problems
during middle childhood (e.g. ADHD), and low IQ around age three (Edwards et al.,
2010; Perera & Herbstman, 2011; Perera et al., 2014).
History of PAH Toxicity
Andersson & Achten (2015) provide a detailed summary of the history of PAH
toxicity as well as guidance for what is in store for future research with polycyclic
aromatic compounds (PACs). From the early 1970’s when the EPA released their list of
16 priority PAHs there has been targeted focus on this group to study and monitor in the
environment. This list became the gold standard for overall PAH toxicity with BaP
serving as the most potent among the PAH class and the most widely studied, especially
for carcinogenesis. One of the arguments made by Andersson & Achten (2015) however,
is the recent findings about the potency of other compounds such as dibenzo[a,l]pyrene,
dibezo[a,i]pyrene and benzo[c]flourene, where they have a carcinogenic potential about
10 to 20 times that of BaP (Greim, 2008). Thus, expansion to the suite of PAHs as
priority compounds to consider in regulatory potential and research is warranted.
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The efficiency of the 16 priority PAHs and their suitability for toxicological study in
the environment must not be overlooked and revising the list of priority PAHs is not an
easy undertaking, although there are known PAHs of greater toxicity. For example, in
contaminated sites that have already undergone cleanup requiring significant investment,
additional regulatory efforts around a new list of PAHs could invalidate genuine efforts
from the past and in turn require additional resources. Still, the consensus among PAC
researchers is the need to expand the list since it is now evident the list is too narrow.
Air Quality Guidelines for PAHs
Guidelines for PAH concentrations in the air is of increasing relevance
considering the arguments made above by Andersson & Achten (2015) as well as the
increase in COPD associations with air pollution levels lower than various national and
international guidelines (Liu et al., 2016).
Indoor air quality guidelines for PAHs were established by the WHO in 2009
(Choi et al., 2010). Citing primary epidemiological findings, again and mainly from
occupational studies, thresholds for PAH exposure were classified according to their
BaP-equivalence since lung cancer posed the most severe health risk from PAH exposure
and BaP the most significant carcinogen documented in the epidemiological literature.
Thus, the indoor air guideline for PAH compounds was estimated at 8.7 x 10-5 per ng/m3
of BaP. Additionally, the lifetime cancer risk for a lifetime of exposure was generated at
1/10,000, 1/100,000, and 1/1,000,000 to be 1.2, 0.12, and 0.012 ng/m3 respectively (Choi
et al., 2010).
According to the ATSDR, the Occupational Safety and Health Administration
(OSHA) provides the regulatory guidelines for maximum PAH exposure in the
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workplace for the U.S. The permissible exposure level (PEL) for PAHs are not
substance-specific and are regulated primarily under OSHA’s air standards for coal tar
pitch volatiles (CTPVs) and coke oven emissions (ATSDR, 2009). The PEL for PAHs
according to OSHA for the workplace is 0.2 mg/m3. This is an eight hour time weighted
average (TWA) measured from CTPVs. A separate standard exists for coke oven
emissions (0.15 mg/m3). It is important to note that other federal agencies in the U.S.
such as the EPA and the National Institute for Occupational Safety and Health (NIOSH)
have suggested additional thresholds for safe PAH exposure. For example, NIOSH
recommends the level of safe exposure for PAHs be classified at the lowest detectable
concentration for CTPVs (0.1 mg/m3). For drinking water, the EPA classified a
maximum contaminant level (MCL) for BaP specifically at 0.2 parts per billion (ppb).
Additional MCLs for six other PAHs can be found elsewhere (ATSDR, 2009).
According to the WHO, outdoor air quality guidelines for PAHs in Europe for
example are not specifically recommended since many of the compounds are parts of
complex mixtures. Some are significant carcinogens as they can react with other
compounds and are attached to particles, i.e. PM. The general recommendation therefore
from the WHO is that PAH concentrations in the ambient air should be kept as low as
possible (World Health Organization, 2000). In regards to occupational exposures, the
WHO refers to the same thresholds offered for indoor air guidelines for BaP (8.7 x 10-5
per ng/m3). In spite of the limitations of using BaP alone to measure the carcinogenic
potential of PAHs, the WHO emphasizes that carcinogenic potential will typically be
underestimated. The advantage of a single indicator however is the opportunity that it
affords to generate a baseline that is well documented in the literature. Furthermore, since
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occupational thresholds for BaP are offered, there is evidence for similar risks identified
from studies of individuals exposed to additional combinations of PAHs (World Health
Organization, 2000).
Finally, a review carried out by Liu et al. (2016) on the impacts of air quality
guidelines on COPD sufferers investigated the short and long-term impacts from air
pollution on COPD mortality and morbidity from a global perspective. Primary findings
from the review revealed an association of outdoor air pollution with COPD morbidity
and mortality including such impacts below air quality guidelines of various jurisdictions
around the world. Causes for COPD deaths and other areas of morbidity still occur from
increased levels of incidence in the overall population as well as from exacerbations.
Thus, additional efforts to amend air quality guidelines are warranted.
The Public Health Burden of COPD
Rabe & Watz (2017) provided a recent review of the epidemiology, causes,
pathophysiology, comorbidities, and treatment options for COPD. They reported a range
of global prevalence estimates. The range of results was due to a combination of data
collection methods (spirometry measures vs. surveys). The most recent findings from the
2015 Global Burden of Disease study estimated prevalence around 174 million cases
(GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, 2016) while
previous estimates from 2010 put global prevalence around 384 million cases when using
spirometry collection techniques (Adeloye et al., 2015). Regional prevalence rates for
COPD were reviewed as well. The Americas led with the highest rates at 15 percent in
2010. Additional areas of increased burden of COPD include the regions where a
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percentage increase was observed. These include the Americas again, Eastern
Mediterranean, and Africa (Adeloye et al., 2015).
COPD is typically underdiagnosed according to Rabe & Watz (2017). This is
increasingly observed in non-smokers and patients who are younger, have lower
education, and less severe forms of COPD (Bernd et al., 2015). From a global burden of
disease perspective, COPD ranks third in the number of annual deaths when adjusted for
age with around 3.2 million deaths per year (GBD 2015 Mortality and Causes of Death
Collaborators, 2016). Although COPD is the third leading cause of death, it is often
observed as a comorbidity with cardiovascular disease (ischemic heart disease and
cerebrovascular disease are the first two global leading causes of death) where a third of
the COPD patients die of cardiovascular diseases and a third have limited airflow
(Anthonisen et al., 2005; Calverley et al., 2007; Franssen et al., 2016; Rabe & Watz,
2017). Thus, attempts to acquire more accurate estimates of COPD burden are further
underestimated due to the confluence of comorbidities. Approximately 90 percent of
COPD deaths occur in low and middle-income countries where the exposure to biomass
burning for cooking and heating is of increasing relevance from PAH exposure (World
Health Organization, 2017a).
COPD is observed more frequently in men than in women (Adeloye et al., 2015),
however increases in smoking rates among women in various developed countries, as
well as increases in exposure to biomass combustion in the home for heating and cooking
have the potential to level out the effects of COPD in both genders (World Health
Organization, 2017a). Rabe & Watz, (2017) also presented the conclusions from various
studies that summarize the susceptibility of women to develop respiratory complications
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such as airflow limitation, which ultimately increases the risk of COPD in women (Han
et al., 2007; Luoto et al., 2016; Sørheim et al., 2010).
Tobacco smoking is the primary cause of COPD worldwide with a global
prevalence around 1.1 billion smokers in 2015 (World Health Organization, 2017b). As
smoking rates continue to decline, other risk factors for COPD such as indoor and
outdoor air pollution are increasingly salient (Rabe & Watz, 2017). Furthermore, Salvi &
Barnes (2009) report that on a global scale more people are exposed to biomass fuel
burning than they are tobacco smoke.
An earlier review completed by Mannino & Buist (2007) identified COPD as a
preventable and treatable disorder, however it is not fully reversible which makes it
distinct from asthma. According to the GOLD guidelines, COPD is defined as the
following: “a preventable and treatable disease with some significant extrapulmonary
effects that may contribute to the severity in individual patients. Its pulmonary
component is characterized by airflow limitation that is not fully reversible. The airflow
limitation is usually progressive and associated with an abnormal inflammatory response
of the lungs to noxious particles or gases”(GOLD, 2017). In regards to reversibility
specifically, lung function does not fully reverse in response to bronchodilators, antiinflammatories, or by some other natural means (GOLD, 2017; Mannino & Buist, 2007).
Classification of COPD should be made based on its severity and the specific
characteristics of the individual i.e. genotype, risk factors, etc. Mannino & Buist (2007)
depict COPD as a heterogeneous disorder with varying degrees of pathology, histories,
and comorbidities from person to person. Additionally, they report it is a model “gene-
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by-environment disease” with presentations of comorbid complications, poor cellular
repair, typical response to infections, and growing airway reactivity.
Mannino & Buist (2007) also point out that comorbid diseases with COPD can
add to its prevalence and severity. A variety of diseases that should be considered in the
differential diagnosis of COPD include asthma, congestive heart failure, bronchiectasis,
tuberculosis, obliterative bronchiolitis, and diffuse panbronchiolitis (GOLD, 2017). An
example offered at this point of the review comes from the Burden of Lung Disease
(BOLD) study where COPD prevalence was assessed in 12 multinational sites. The issue
related to comorbid diseases and such effects on prevalence and severity comes from the
BOLD findings where a significantly high COPD prevalence was observed in South
Africa, which also had a high prevalence of tuberculosis (Amaral et al., 2015). Other
important disorders of disease overlap include asthma (a standalone risk factor for
COPD) and popcorn worker’s lung (Kreiss et al., 2002; Lange et al., 1998; Mannino &
Buist, 2007). In regards to COPD severity, GOLD guidelines for spirometric strength
have been described elsewhere (Global Initiative for Chronic Obstructive Lung Disease,
2016). Other factors for COPD severity that were recommended include an overall index
(called the BODE index) made up of a variety of measures including exercise level,
dyspnea score, lung function, and body-mass index (Celli et al., 2004).
Primary risk factors for COPD are controlled by the overlap of environmental
exposures, genotype, and comorbidities (Mannino & Buist, 2007). Risk factors for COPD
can be divided into two groups according to Viegi et al. (2006) – exogenous (air
pollution, tobacco smoke, etc.) and endogenous (genetics, age, gender, etc.). Genetic
factors impacting COPD include deficiencies in the enzyme serine protease α1
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antitrypsin, parental lung function as a potential predictor, and several specific genes
including those that code for microsomal epoxide hydrolase 1, transforming growth
factor β1, and tumor necrosis factor α (Stoller & Aboussouan, 2005). The largest
contributor to COPD across the globe is tobacco use. There is genetic variation when it
comes to COPD and smokers since not all smokers end up developing COPD (Mannino
& Buist, 2007).
Occupationally speaking, COPD is caused by a variety of chemicals, fumes, dust,
and vapors (Trupin et al., 2003). From an indoor air perspective, the main risk factor for
COPD is exposure to biomass burning for heat and cooking. For example, among low
and middle income countries, the WHO approximates over a third (35 percent) of COPD
cases developed from biomass burning indoors (Mathers et al., 2006). Another pollutionrelated risk factor, outdoor air pollution has been associated with COPD, however on a
much smaller level according to Mannino & Buist. Granted, more recent findings reveal
that outdoor air pollution is of greater significance to COPD than once thought (Liu et al.,
2016; Ogawa & Kishi, 2016; Yang et al., 2017a; Zeng et al., 2012). Earlier estimates
assessed outdoor urban air pollution contributing to about one percent of COPD cases in
high income countries and two percent in low and middle income countries (Mathers et
al., 2006).
COPD has been associated with increasing age. As global trends in elderly
populations continue to rise, COPD prevalence, morbidity, and mortality will continue to
follow suit (Jemal et al., 2005). Infections are an additional risk factor and comorbidity
associated with COPD that contribute to its pathogenesis as well. A salient area with this
factor includes infections acquired at a young age which can lead to susceptibilities to
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airway responsiveness and enlargements in the bronchi (Wedzicha & Seemungal, 2007).
As mentioned previously, asthma and gender have been associated as risk factors for
COPD with the latter somewhat controversial in its contribution as tobacco prevalence
shifts between genders and indoor biomass burning continues to persist. (Mannino &
Buist, 2007). The final risk factor identified by Mannino & Buist (2007) in their review
was socioeconomic factors. Poverty alone was identified as a proxy while specific factors
such as nutrition status, crowding, and access to healthcare were more telling (Antó et al.,
2001; Lawlor et al., 2004; Shohaimi et al., 2004). Furthermore, just as COPD is more
likely to occur among the poor and less educated, similar findings have been found with
lung cancer (Punturieri et al., 2009).
The economic burden of COPD in healthcare costs as well as lost productivity
have been similarly challenging to estimate as with prevalence since reporting measures
and data collection methods vary from country to country or jurisdiction to jurisdiction. A
measure utilized by the WHO, quality-adjusted life years of improvement, assesses the
cost of individual interventions, in this case for COPD. For the ipratropium inhaler, a
medication used to open up medium to large airways in the lungs, quality-adjusted life
years of improvement ranged from $6,700 to $8,900 and $13,400 for other corticosteroid
inhalers, as well as $238,200 for lung transplants (Mathers et al., 2006). Mannino & Buist
(2007) indicate that smoking cessation is likely to be highly cost-effective; however
economic evaluations for this intervention were unknown at the time of their review.
Direct medical costs for COPD in the U.S. were presented with per patient costs around
$2,700 to $5,900 for attributable costs and $6,100 to $6,600 for excess costs (Foster et
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al., 2006). Total costs in the U.S. were estimated at $32.1 billion (direct costs were $18
billion) (Devine, 2008).
Mannino & Buist conclude their review of COPD with a focus on future trends.
They address improvements in disease classification and treatments as well as the
continued challenges of prevalence and burden estimates. They reiterate the prediction of
the impact of smoking prevalence shifts and suggest treatment options such as enhancing
smoking cessation, improved antioxidant treatments, using biological agents to target
cellular activity, as well as other interventions to decrease lung hyperinflation. Finally,
they suggest that population changes with a significantly larger elderly subpopulation
will make COPD one of the most important chronic diseases of the future and will
become more prevalent with a greater need for managed care and prevention efforts in a
potential era of essential resource stewardship (Edward H. Wagner, 2004; E. H. Wagner,
1998).
Patel et al. (2014) assessed the indirect costs of COPD to employers and
individuals in the U.S. Primary findings indicated COPD generates significant indirect
costs that are burdensome to employers from lost productivity and for individuals who
lose income due to disability and absenteeism. Some of the quantitative findings include
annual sick leave for individuals with COPD ranged from 1.3 to 19.4 days with indirect
costs of $1,521 to $3,348 per person. Additionally, the percentage of indirect costs out of
the total costs associated with COPD ranged from 27 to 61 percent (Patel et al., 2014).
COPD trends for outcomes, financial burden and mortality from acute
exacerbations was assessed by Jinjuvadia et al. (2017). They found that COPD accounted
for 3.2 percent of all hospitalizations in 2002 and 3.4 percent in 2010 in the US. Although
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this was not statistically significant there was a significant increase in secondary
diagnoses of COPD hospitalizations between 2002 and 2010. Mortality and length of inpatient hospital stays were observed to decrease during this time period, form 4.8 percent
to 3.9 percent, and from 6.4 days to 6.0 days respectively. However, in spite of the
observed decreases, hospitalization cost per patient grew considerably from $22,187 to
$38,455 (Jinjuvadia et al., 2017).
Multimorbidity is the presence of two or more chronic conditions and is
frequently observed in individuals with COPD (Westney et al., 2017). Attempts at
evaluating the impact of this on the healthcare system have been made since the
assumption is that a greater burden is placed on state health programs like Medicaid when
serving a multimorbid population. Specifically, Westney et al. (2017) sought to quantify
the cost of COPD with additional comorbid diseases among the national Medicaid
population in the U.S. Some of their findings include an increase in acute care, hospital
bed stays, and total costs as multimorbidity increased. Interestingly, emergency
department (ED) visits were less common for COPD than they were for other
morbidities. Some of the comorbidities identified with COPD were asthma,
hyperlipidemia, affective disorders, diabetes, and hypertension. Several reasons for ED
visits for patients with COPD were identified including asthma, congestive heart failure,
and substance abuse. Finally, females were identified with COPD-associated ED visits
(as well as non COPD-associated ED visits) (Westney et al., 2017).
Ding and Enstone (2016) reviewed the literature on the comorbidity of asthma
with COPD. Citing the Gold guidelines as well as the Global Initiative for Asthma
(GINA), they identify that Asthma and COPD Overlap Syndrome (ACOS) is a frequent
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term used to define such individuals. Other terms used to label patients with this
comorbidity include mixed COPD-asthma, asthma that complicates COPD, COPD with a
prominent asthmatic component, and Asthmatic bronchitis (GINA & GOLD, 2015; Louie
et al., 2013). The significance of ACOS is the understanding of the increased burden this
syndrome has on patients, the healthcare system, and society in general. ACOS sufferers
are viewed as having a greater severity in their morbidity which has a corresponding
impact on healthcare (Louie et al., 2013). Estimates of ACOS prevalence ranged from 12
to 55 percent and economic burden for Medicaid patients for asthma, COPD, and ACOS
were $2,307, $4,879, and $14,914 respectively (Ding & Enstone, 2016; Shaya et al.,
2008).
COPD’s impact to women is a growing disparity observed in the U.S. According
to Mehari & Gillum (2015), the number of COPD deaths per year is higher in women
than in men and the mortality rate for African-American women was about half of the
rate observed in European-American women. Additionally, healthcare utilization for
COPD was higher for women than for men in emergency room visits and hospitalizations
(Mehari & Gillum, 2015).
Biological Pathway of COPD Caused by PAHs
Recent studies have demonstrated an increased risk of outdoor air pollution as a
contributor to COPD. Diaz-Guzman and Mannino (2014) suggest in their review of
COPD risk factors that indoor air pollution is especially salient for COPD pathogenesis,
however they contend outdoor air pollution’s contribution is increasingly evident. For
example, the ESCALA study explored the connection between outdoor air pollution and
mortality in nine Latin American cities (Romieu et al., 2012). The results revealed a

26

“positive statistically significant association between PM10 and all-natural-cause
mortality” with COPD having the highest percentage increase in mortality (Romieu et al.,
2012).
When it comes to outdoor air pollution and PAHs specifically, their association
with PM2.5 as well as ultrafine particles (UFPs; diameter less than 100nm) has been
demonstrated to increase the likelihood of COPD occurrence (Gan et al., 2013; Yang et
al., 2017; Zhang et al., 2017). A longitudinal study to assess the impact of traffic-related
outdoor air pollution was carried out in Vancouver, Canada assessing exposures to black
carbon (BC), PM2.5, NO2, NOX, and woodsmoke. The findings revealed a 6 percent and
7 percent increase for COPD hospitalizations and mortality from BC respectively, and a
15 percent increase for hospitalizations from woodsmoke after adjusting for known
potential confounders. Additionally, positive associations with all traffic-related air
pollution compounds in the study were observed (Gan et al., 2013). Furthermore, it is
important to note that PAHs are a primary toxic component of woodsmoke as they are
released from the combustion of organic carbon.
A recent study completed by Zhang et al. (2017) examined the impact of PM and
PAHs on diagnosed COPD patients in Peking, China. Specifically, UFPs and PAHs were
significantly associated with an oxidative stress biomarker in the COPD cases observed
where interquartile ranges for BC, UFPs, and PAHs had increased associations with the
biomarker of 87 percent, 69 percent, and 156 percent respectively (Zhang et al., 2017).
Viegi et al. (2006) report that air pollution plays a salient role in the pathogenesis
and exacerbation of COPD and is a significant cause of COPD morbidity and mortality.
In their review of COPD and air pollution they present several primary studies
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demonstrating the links between outdoor air pollution and adverse health outcomes
including COPD. A follow-up study carried out in the U.S. that assessed over 500,000
people indicated that an increased risk of all-cause mortality, cardiopulmonary, and lung
cancer mortality were associated with increased elevations of PM2.5 (Pope et al., 2002).
According to Viegi et al. (2006), additional studies demonstrating an association of
mortality with outdoor air pollution include (Biggeri et al., 2004; Forastiere et al., 2005;
Gryparis et al., 2004; Hoek et al., 2002; Künzli et al., 2000) as well as associations with
morbidity i.e. exacerbations and hospitalizations, to include (Anderson et al., 1997;
Baldacci et al., 1997; Iversen et al., 2005; Schikowski et al., 2005; Yang et al., 2005).
The biological mechanism and pathway for COPD as well as lung cancer
pathogenesis following PAH exposure has been extensively studied when mediated
through tobacco smoke (DHHS, 2014). Kaur-Knudsen et al. (2012) identify the specific
role that several genetic factors play in causing adverse health outcomes from PAHs in
tobacco smoke. Cytochrome P450 1B1 and 2C9 genes are typical metabolizers of PAHs
which then lead to metabolites that cause tobacco-related disease and more importantly
when it comes to outdoor air pollution and PAH-related diseases (Kaur-Knudsen et al.,
2012). Pauk et al. (2013) note that PAHs are not directly genotoxic for humans in the
sense that they must be metabolized first by the cytochrome P450 family. In addition to
1B1 and 2C9, 1A1 and 1A2 are associated in the carcinogenic pathway to initiate DHA
adducts leading to potential mutation.
To evaluate the specific mechanism and pathway in which PAHs from outdoor air
pollution contribute to COPD pathogenesis, Yang et al. (2017) assessed haze events in
China and the associations of COPD in the population. They propose the primary avenue
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for PAHs to initiate the genesis of disease in those exposed occurs through the aryl
hydrocarbon receptor pathway. The aryl hydrocarbon receptor pathway enables the
effects of oxidative stress to take place; oxidative stress being a main element in COPD
pathogenesis and carcinogenesis with lung cancer as well. In their study, Yang and
colleagues utilized PM2.5 extracts collected during haze events and exposed them to
human lung epithelial cells. The extracts were observed to induce oxidative stress causing
DNA damage that lead to inflammation demonstrated by the generation of cytokines
from BEAS-2B cells in addition to a reduction in α1-antitrypsin expression. Again, the
main elements of PM2.5 that generated these impacts were primarily those from PAHs,
specifically those with high BaP-equivalent concentrations (Yang et al., 2017). In
addition to the genetic investigation carried out, Yang and colleagues assessed individual
associations with COPD and PAHs. They identified that high BaP-equivalent
concentrations of PAHs increased the likelihood of COPD.
Other studies have assessed the impacts of chronic exposures to air pollution with
COPD as the primary health outcome of investigation. For example, Atkinson et al.
(2015) evaluated an English cohort of individuals not diagnosed with COPD from 2003
to 2007. They found inconclusive evidence of chronic associations with COPD from air
pollution. Conversely, a potential association was found by Andersen et al. (2011) in their
study of traffic-related air pollution (specific for NOX) and COPD occurrence among a
Danish cohort of some 57,000 individuals between 1971 and 2006.
General Comorbidities
The following section begins with a summary of COPD comorbidities and their
effects. Additionally, a specific focus on lung cancer co-occurrence is presented where
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the bulk of the subsequent sections will include a specific environmental epidemiological
emphasis on lung cancer as a comorbidity with COPD.
According to Corlateanu et al. (2016), the most common comorbidities with
COPD include “skeletal muscle wasting, cachexia (loss of fat-free mass), lung cancer
(small cell or non-small cell), pulmonary hypertension, ischemic heart disease,
hyperlipidemia, congestive heart failure, normocytic anemia, diabetes, metabolic
syndrome, osteoporosis, obstructive sleep apnea, depression, and arthritis.” The
interactions among these comorbidities result from a variety of factors such as chronic
and systemic inflammation, low levels of oxygen (hypoxia), as well as various other
genotypic and environmental factors.
Putcha et al., (2015) report that over 80 percent of individuals with COPD have at
least one comorbidity and that specific-comorbidity or multimorbidity has only recently
been considered in treatment management. Findings from Dursunoğlu et al. (2016),
revealed that about half of all COPD sufferers have three or more comorbidities while
such comorbidities have a variety of impacts including added complications, reduced
quality of life, changes in symptomology, treatment/management variations, as well as
economic impacts i.e. added health care costs and lost productivity.
Lung Cancer Comorbidity, Prevalence, Mortality, and Demographics
The overlap of COPD and lung cancer is well established. Wang (2013)
summarized that the process of COPD occurrence in an individual is brought about by a
“series of complex interactions between noxious airborne agents together with a genetic
predisposition.” Cigarette smoke, air pollution, in addition to infectious agents is
typically connected with COPD. Much of the same is summarized for lung cancer.
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According to Putcha et al. (2015), the prevalence of COPD in lung cancer patients
is around 50 percent while the prevalence of lung cancer in COPD patients is estimated
around four to eight percent. A study by Skillrud et al., (1986) investigated the risk of
lung cancer in COPD sufferers with a case control study. They found that approximately
one percent of patients with COPD acquired lung cancer each year where only 0.2
percent of non-COPD patients acquired lung cancer annually, indicating a five-fold
increase of lung cancer among COPD patients. Lung cancer comorbidity was assessed by
Divo et al. (2012), one of the few prospective studies identifying the links between
COPD and lung cancer (Wang, 2013). They followed up with COPD patients (N=1,664)
over the course of four years and identified 79 comorbidities. Lung cancer showed the
strongest association with nine percent prevalence.
Putcha and colleagues report several studies demonstrated that lung cancer is a
significant cause of death among individuals with COPD (Anthonisen et al., 2005a;
Mannino, Doherty, & Buist, 2006; Mannino, Thorn, Swensen, & Holguin, 2008).
Additionally, Dursunoğlu et al. (2016) reveal that lung cancer and cardiovascular disease
have a disproportionate effect on COPD mortality where indices such as the Charlson
Comorbidity Index and the COPD Specific Comorbidity Index (COTE) have proved
effective in their predictive power for COPD mortality. Explanations for the excess risk
of lung cancer mortality in COPD patients include associations with shared genetic loci,
epigenetic modification of bronchial cells following exposure to tobacco smoke or air
pollution, or systemic inflammation in sufferers with COPD, which can predispose
people to lung cancer (Dursunoğlu et al., 2016; Rooney & Sethi, 2011; Wauters et al.,
2011).
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Demographic application regarding the overlap of COPD and lung cancer reveals
disproportionate effects in gender. Ben-Zaken Cohen et al., (2007) investigated the
growing burden of COPD and lung cancer in women, reporting there is a worrying trend
for both diseases among females. For example, the annual COPD mortality rate increased
by 291 percent among women in the U.S. between 1980 and 2000, along with a hospital
rate increasing by 43 percent. Whereas, men in the U.S. had COPD mortality and hospital
rate increases of 60 percent and 12 percent respectively (Mannino et al., 2002). Lung
cancer was identified as being no less alarming with the highest mortality rate of cancer
among women (60 percent more than breast cancer) (Jemal et al., 2005). Additionally,
the U.S. female mortality rate for lung cancer rose from 38 percent to 41 percent between
1991 and 2005, while the male rate decreased from 91 percent to 69 percent over the
same period (Jemal et al., 2009).
COPD is a standalone risk factor for lung cancer, specifically for squamous cell
carcinoma (Papi et al., 2004). Additionally, lung cancer is upwards of five times more
likely in smokers with a chronic airway pathology versus those with no pathology
(Young & Hopkins, 2010). Wang (2013) identified that COPD is the single most
important risk factor for lung cancer after adjusting for cigarette smoking when forced
expiratory volume (FEV1) is used for diagnosis. In a study carried out by Calabrò et al.
(2010), reduced FEV1 revealed an increased risk from lung cancer where a small
reduction of 10 percent in FEV1 demonstrated almost a three-fold increase in lung cancer
probability. Other studies have isolated the risk of lung cancer from COPD independent
from smoking such as van Gestel et al. (2009) and Rodríguez-Roisin & Soriano (2008).
Both were cohort studies where van Gestel and colleagues identified significant increases
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of lung cancer occurrence among COPD patients, where Rodríguez-Roisin & Soriano
identified increased risks of mortality from lung cancer among COPD patients.
Oxidative Stress. Inflammation, and Hypoxia Mechanisms
Proposed mechanisms for the correlation of COPD with lung cancer include
genetic predispositions to disease and other pathogenic influences in addition to other
mechanisms such as premature aging (Barnes & Adcock, 2011). COPD and lung cancer
are closely linked at a molecular level as they share common pathways for activation i.e.
inflammation (Durham & Adcock, 2015). Most cancerous tissues demonstrate
inflammation, while a number of inflammatory diseases can lead to cancer (Schetter et
al., 2010). Tuder et al., (2012) and Caramori et al. (2011) have demonstrated that
inflammation is causative in both COPD and lung cancer. In an article by Roca et al.
(2012), the link between COPD and lung cancer is discussed in light of the
commonalities and co-occurrence of the two diseases. Oxidative stress and inflammation
are cited as the shared pathogenic mechanisms; however the implications of their
common risk factors (i.e. smoking) suggest genetic susceptibilities act in concert together
to initiate biochemical processes for pathogenesis. It is important to note that air pollution
is an identified risk factor that influences this mechanism for pathogenesis, however it is
not specified by Roca et al. (2012).
A historical perspective on the links between COPD and lung cancer is provided
by Prevot et al. (2012) where prior to the late 1990’s the mechanisms for pathogenesis
between the two diseases were thought to be unique. As discussed above, the data over
the past twenty years have demonstrated the commonalities in such mechanisms. Prevot
et al. (2012) identified that COPD and lung cancer appear to have a genetic basis that
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predisposes individuals to environmental exposures that can result in the pathogenesis of
either or both diseases. They expound that the identified commonalities for pathogenesis
between the two diseases include “genetic and epigenetic abnormalities, mechanical
factors, and signalization pathways.”
Boots et al. (2003) discuss the cyclical effect that oxidative stress and reduced
antioxidant resources can have on both COPD and lung cancer. They report that several
indicators of oxidative stress (i.e. hydrogen peroxide exhalation, degraded proteins, etc.)
are increased among individuals with COPD and what results is reduced antioxidant
capacity in the individual. Additionally, as this capacity decreases in the blood its effects
circulate throughout the body indicating a systemic effect. Additional contributors for this
effect include cell death (apoptosis) and inflammation. As mentioned above, lung cancer
is influenced through these same pathways of oxidative stress and inflammation.
According to Vineis & Husgafvel-Pursiainen (2005), PAHs are a significant
component of PM in air pollution that bring about oxidative stress and subsequent
damage to DNA. They go on to identify that the basis of evidence from oxidative damage
to DNA in lymphocytes from air pollution exposure points to one of the major products
of DNA oxidation, 8-oxo-dG, revealing it as one of the important mutation-causing
lesions. Additionally, since oxidative stress has been identified as playing a role in COPD
for some time including the specific role of 8-oxo-dG, the connection of the root causes
between the two pathologies is further evidenced (Aoshiba et al., 2012; Nemoto et al.,
2014; Yang et al., 2014).
Specific elements of lung cancer carcinogenesis from PAH exposure include the
production of DNA adducts (following PAH metabolism), the creation of oxidative harm
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to DNA, chromosomal shifts, and an involvement in the changes to oncogenes and tumor
suppressor genes (Farmer et al., 2003; Pauk et al., 2013). In a study carried out by Pauk et
al. (2013), PAH exposure and its influence on lung carcinogenesis and COPD was
investigated by looking at PAH induced antibodies in human blood. Their rationale, when
PAH exposure occurs and DNA adducts are created, antibodies are produced by the
immune response. The benefit of measuring this is the potential for an additional
biomarker for PAH exposure in future studies to pinpoint carcinogen-specific antibodies.
Additionally, if the chronic load of PAH exposure is large enough in cases like tobacco
smoke and air pollution exposure, the body’s immune response is compromised and antiPAH antibodies are less prevalent, therefore creating a context in which the exposed is
less able to protect against the toxic effects of PAHs from the environment (Pauk et al.,
2013). The study concluded that the genotoxic risk of chronic exposure to PAHs
increases in settings that have dense concentrations of PAHs from tobacco smoke or
other forms of PAH pollution.
The linkage between oxidative stress and inflammation was expounded upon by
Wang (2013), where air pollutants cause oxidative stress to the lungs giving rise to
reactive oxygen species (ROSs), which can then overcome antioxidant capacity, as
mentioned by Boots et al. (2003) above. When this capacity is overrun, ROSs react with
various elements, such as DNA, to initiate the disease process. In the case of
inflammation, air pollutants can react with ROSs which then can activate mitogenactivated protein kinase (MAPK) signaling, which ultimately encourages inflammation.
For ROSs to occur in the body, inflammatory cells release them (in the lungs in this case)
leading to increased inflammation, tissue damage, and other harmful impacts. The
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interaction between inflammation and oxidative stress is highlighted among phagocytes
as they are activated by particulate matter collecting in the lungs, whereby ROSs are
released and oxidative stress ensues (Wang, 2013).
An in vivo study carried out by Karoor et al. (2012) hypothesized that hypoxia in
the lungs, which is present in COPD patients, can increase the risk of lung cancer
development. Mice were exposed to hypoxic environments during the study and
demonstrated an increase in tumor development compared to controls that were exposed
to normal oxygen levels. They concluded that tumors developed in the hypoxic
pulmonary context of COPD sufferers, demonstrating amplified growth, angiogenesis
(blood vessel formation), and survival signaling. What can result from these
demonstrations is an increased risk of lung cancer among individuals with COPD.
Genetic Influences
Genotype plays a significant role in both COPD and lung cancer. Inherited
susceptibility to COPD and lung cancer is a primary component to understanding the
overlap of both diseases. Young et al. (2011) indicate heritability of COPD is between 40
and 77 percent, where lung cancer heritability is between 15 and 25 percent. The
presence of COPD comprises an important phenotype that affects a significant portion of
people with lung cancer as well as an influential impact on lung cancer susceptibility
(Wang, 2013).
Specific genes that have been identified in playing a role in lung function and COPD as
well as those with susceptibility to COPD and lung cancer have been identified in several
linkage studies (Wang, 2013). Findings from these studies include markers on
chromosome 6q in regards to lung cancer and abnormal lung function, in addition to
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chromosome 12 influencing lung cancer, COPD, and lung function. Other genes for
susceptibility were identified to be influential in “detoxification, immune regulation,
matrix remodeling, DNA repair, cellular proliferation, and tumor suppression” (Caramori
et al., 2011; Wang, 2013).
Expounding on the work of Kaur-Knudsen et al. (2012) and Pauk et al. (2013)
with cytochrome P450, and delving further into the similarities of the biologic
mechanisms between lung cancer and COPD, the PAH-metabolizing enzyme - CYP1A1
(also known as cytochrome P450B1) which is a known aryl hydrocarbon hydroxylase,
has been isolated in tissues throughout the body including the lungs, skin, intestines, liver
as well as other cellular material (Wang et al., 2015A). Significant associations between
the CYP1A1 polymorphism and COPD have been identified with various impacts such as
susceptibility and overall risk for COPD (Wang et al., 2015B). Moreover, the same
mechanism and impacts of CYP1A1 have been demonstrated with lung cancer (Lao et
al., 2014).
Polymorphisms, specifically single nucleotide polymorphisms (SNPs) can be
identified in their association with disease susceptibility. Thus, certain genetic variations
can lead to disease susceptibility if an individual or group of individuals have the same
genotypes. Matullo et al. (2006) investigated the association of certain polymorphisms
that occur in DNA repair genes following air pollution and environmental tobacco smoke
exposure. They provide an example using PAHs (as well as other known air pollution
carcinogens) where DNA adducts are primary genetic responses to exposure, however
other responses such as interstrand cross-links and ROSs can lead to lesions resulting in
mutations and subsequent cancer risk if unrepaired (Vispe et al., 2000). The health
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outcomes studied by Matullo and colleagues included various cancers (including lung) as
well as COPD mortality. The results of specific polymorphisms with the corresponding
health outcomes (including lung cancer and COPD) were inconclusive, indicating there
were no statistically significant associations among the SNPs and the various health
outcomes in the study. Adding to the work of Matullo and colleagues includes additional
null findings found by Kaur-Knudsen et al., (2009). They further expound on
insignificant associations of polymorphisms with cardiopulmonary diseases and cancer.
Specifically, they investigated cytochrome P4501B1 (*3 and *4 polymorphisms) and
found no associations with COPD, various cancers (including overall cancer, tobaccorelated cancer, and female cancer), myocardial infarctions, ischemic heart disease, or
ischemic cerebrovascular disease.
The work of Shen et al. (2008) examined SNP associations with COPD in a
population with significant exposure to indoor smoky coal emissions. They investigated
18 SNPs in 10 cytokine genes and associated these with COPD risk. They found
significant associations of 2.4 and 2.7 fold higher risks for the CSF2 117lle allele and the
AA genotype at IL8 -351 respectively. These findings suggest that the specific
polymorphisms mentioned above play a role in the pathogenesis of COPD. Furthermore,
it is important to note that the same population used in this study in China came from one
of the areas with the highest rates of lung cancer in the country and the same controls that
matched for COPD cases in this study were used to match to lung cancer cases in a
separate investigation (Shen et al., 2008). Additionally, the work of Rudisch et al. (2015)
found similar results with CSF2 and non-small cell lung cancer (NSCLC) associations;
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specifically where CSF2 played a significant role in the inflammatory pathway of
NSCLC.
Lung Comorbidity and Air Pollution
A review by Wang (2013) summarized the significant literature linking COPD
with lung cancer. They report that COPD and lung cancer associations are easily found in
the literature. Several examples were provided that identified air pollution as an
environmental factor in the pathogenesis for both diseases, although tobacco smoke was
the most significant causative factor identified. The mechanisms resulting from air
pollution that were recognized include oxidative stress and inflammation.
PAHs, BaP specifically, was mentioned by Wang (2013) for its presence in both
cigarette smoke and air pollution. Its specific impact on COPD was linked to the increase
in proliferation of certain lung cancer cells through the epidermal growth factor receptor
(EGFR). This proliferation can take place as the epithelial cells in the lungs are exposed
to cigarette smoke leading to chronic EGFR activation where this protracted signaling
contributes to unrestrained cell growth. In regards to proliferation, it is unclear if this has
a significant role in the pathogenic potential of COPD.
Considering air pollution from a broader perspective at a lesser granularity than
PAHs alone, particulate matter in general has been identified in lung cancer tissue with
several studies looking at such impacts (Wang, 2013). Caramori et al. (2011) identified
how increased deposition of PM was present in the major bronchi with the use of
computer models of the lungs of COPD patients. Additionally, Ling et al. (2011)
established that PM was present in the lung parenchyma, blood vessel walls, airways,
lymphoid follicles, and alveolar macrophages. Primary findings here described PM as
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ubiquitous in the lung tissues of COPD sufferers and that exposure to PM from tobacco
smoke in particular was associated with PM retention. This is of specific interest for
disease severity as the lungs of patients with COPD have a decreased capacity to expel
PM, where this retention could then lead to increased severity. It is important to note this
latter example from Ling and colleagues did not specify the role of lung cancer resulting
from PM with specific pulmonary deposition, however this literature can be found
elsewhere i.e. Saieg et al. (2011) and Tokiwa et al. (1998).
Although several null findings were briefly touched on previously, the specific
causal factors associating PAHs with COPD and/or lung cancer has gone through a
portion of scrutiny with reviews such as Marino et al. (2015) and Connellan (2017),
especially in regards to chronic exposure. Their conclusions suggest that although there
are clear toxic effects from hydrocarbon exposure via air pollution, what is required is
more definitive research to link the effects of longer term and lower exposure detailing
the specific mechanisms of such toxicity over time. These are valid limitations to a
portion of the literature mentioned above, however studies such as Pauk et al. (2013),
Boots et al. (2003), and Vineis & Husgafvel-Pursiainen (2005) provide evidence to the
contrary detailing the toxic load over time from PAHs, especially when it comes to the
pathogenic potential from oxidative stress. Furthermore, this is an area the current
research is proposing to investigate.
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CHAPTER 2
ESTIMATING THE STRENGTH OF ASSOCIATION AMONG COPD
LUNG CANCER ATTRIBUTABLE TO PAHS USING NHANES
Chapter two assessed the associations of PAHs with COPD and lung cancer to
isolate an environmental etiology distinct from tobacco smoke. The primary assumption
of this investigation was PAH exposure occurring from air pollution. However, in light of
the environmentally ubiquitous quality of PAHs in the soil, food sources, water, etc., air
pollution exposure could not be isolated as the sole source. The next section outlines the
evidence base for using the National Health Assessment and Nutrition Examination
Survey (NHANES) to associate PAHs and health outcomes, including the presence of
COPD or lung cancer. Afterward, the methodology for the analysis is provided, and
finally the results are presented.
PAH Metabolite Analysis Justification
The biological basis for using PAH metabolites to assess associations with health
outcomes is well defined in the literature. This is demonstrated specifically with studies
utilizing NHANES laboratory, examination, and questionnaire data. Numerous
investigations have explored the health effects and various associations with PAH
metabolites using NHANES i.e. Alshaarawy et al. (2014); Farzan et al. (2016); Kim et al.
(2014); Liu et al. (2016); Scinicariello & Buser. (2014); Xu et al. (2010), etc.
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While the studies above were not all intentionally assessing ambient air pollution
exposure using PAH metabolites as a biomarker, additional studies assessing routes of
exposure from PM2.5/PAHs and resulting PAH metabolites in the urine include (Bekki et
al., 2012; Hayakawa et al., 2011, 2017; Motoyama et al., 2009). Specifically, Hayakawa
et al. (2017) reviewed the recent studies investigating PAH metabolites, their oxidative
potential from air pollution, and the resulting health impacts such as the production of
ROSs. They discuss the importance of these studies in regards to the growing health
concerns from PM2.5 and summarize the established literature on exposure pathways and
biological mechanisms for PAH metabolites.
Earlier work in this area includes Lee & Kang (2008) where they investigated a
particular urinary PAH metabolite, Urinary 2-napthol, and summarized its usage as a
biomarker of ambient particulate matter exposure and specific associations with COPD
and lung cancer. Further investigations of theirs tested the stability of Urinary 2-napthol
as a biomarker for air pollution exposure indicating its strong utility in epidemiological
studies in the realm of PAH exposure from air pollution and resulting COPD and lung
cancer associations.
Zhou et al. (2016) expound on the nuance between general exposure to ambient
PAHs and associations with respiratory pathologies versus the association with PAH
metabolites and respective pathologies. They investigated this difference by assessing a
sample of the general Chinese population and the relationships between urinary PAH
metabolites and corresponding lung function. Specifically, they measured 12 urinary
PAH metabolites in 2,747 participants and analyzed associations using mixed linear
models. Their findings revealed significant associations with PAH metabolite
concentrations and reduced lung function using forced expiratory volume after one
42

second (FEV1) as the primary measure. The significant PAH metabolites they assessed
included 2-hydroxynaphthalene, 9-hydroxyfluorene, 2-hydroxyfluorene, 4hydroxyphenanthrene, 9-hydroxyphenanthrene, 3-hydroxyphenanthrene, 1hydroxyphenanthrene, 2- hydroxyphenanthrene, and 1-hydroxypyrene. The largest
individual PAH metabolite associations leading to reduced lung function included 2hydroxyfluorene, 4-hydroxyphenanthrene, and 1-hydroxyphenanthrene (41.76-, 36.87and 39.53- ml reduction in FEV1 respectively). The total urinary PAH metabolite
influence on lung function was 37.13-ml reduction in FEV1. Additional areas of inquiry
in the study included traffic exposure time and dietary PAH exposure, which both
revealed positive associations to urinary PAH metabolite concentrations.
In light of these various studies as well as the ones mentioned in the introduction
in regards to NHANES investigations with COPD, lung cancer, and PAHs, there has not
been an investigation into spirometry-confirmed COPD associations with PAHs, nor has
there been an investigation into the overlap of all three of these areas within NHANES.
Furthermore, there have been no cross-sectional studies of this size that analyzed the
associations of all three. As such, the following methodology is proposed using the
various analytical approaches of Mannino et al., (2003); Shiue, (2016); and Tilert et al.,
(2013).

Methods
The foundation for chapter two’s analysis was based on the analytical approach
identified by Shiue (2016). The focus of the study used the two principal disease
categories of chronic bronchitis and emphysema for COPD and then analyzed
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associations with urinary PAHs from NHANES laboratory data. For the analysis, data
was obtained from CDC’s NHANES data portal
(https://www.cdc.gov/nchs/nhanes/index.htm) for years 2007, 2009, and 2011. While
PAH laboratory data as well as medical condition data like chronic
bronchitis/emphysema have been collected more recently and even prior to 2007, these
years correspond to the most recent survey iterations when spirometry measures were
collected. The NHANES web tutorial was followed for downloading NHANES data as
SAS transport files, appending, merging, cleaning and recoding, formatting and labeling,
and saving data sets.
Mirroring Shiue’s study, the statistical procedures employed in the analysis
included chi square tests for independence and logistic regression. Log transformation
was used since urinary PAH concentrations from NHANES were highly skewed (Shiue,
2016). Primary covariates understood as potential confounders included age, sex, ratio of
family income to poverty (socio-economic proxy), BMI, education, urinary creatinine,
serum cotinine (tobacco biomarker), alcohol consumption, and physical activity level.
It is important to reiterate that Shiue (2016)’s study did not incorporate the use of
spirometry as a confirmation of COPD diagnosis nor was COPD addressed in the study in
general, although chronic bronchitis and emphysema are the two primary types of COPD
categories, yet COPD as a term has been used since the 1960s (CDC, 2016; Petty, 2006).
Additionally, COPD as a classification within NHANES was not explicitly asked on the
questionnaire portion of the survey until 2013. Finally, Shiue did not include covariates
for secondhand smoke exposure or former smokers, which were additional covariates
included in this study.
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The first objective of this chapter was a synthesis of the methodologies of the
studies mentioned above to measure the association between PAHs and COPD.
Specifically, urine samples measuring PAH levels from NHANES were analyzed
alongside participants’ spirometry readings at levels indicating a COPD diagnosis
according to the GOLD spirometry test guidelines (Global Initiative for Chronic
Obstructive Lung Disease, 2016). Spirometry data were utilized as a continuous variable
and were analyzed alongside PAH measures (also continuous variables) to investigate
whether a significant association was present. Self-reported COPD was also included in
an overall COPD measure that was combined with the spirometry-confirmed COPD
variable and was used in the model as the primary dependent variable.
The second objective for this chapter was to measure the association between
PAHs and COPD occurrence among smokers versus non-smokers.
The third and final objective: isolate a distinct environmental etiology from PAH
exposure using COPD and lung cancer comorbidity as the outcomes.
Finally, no funding was required for this analysis as NHANES data is public
access and the analysis software (SAS 9.4) was acquired in-kind. Although IRB approval
was not required by the CDC to gain access to the NHANES data portal, the University
of South Carolina IRB review process was followed including completing the
Collaborative Institutional Training Initiative’s (CITI) web-based human research course
titled Social and Behavioral Researchers (and subsequent certification) as well as
completing an expedited IRB review and approval due to the data’s secondary and deidentified nature.
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Methodology Summary
Goal: To determine whether there is an association of PAHs and spirometryconfirmed COPD and/or lung cancer as a means to determine a potential environmental
etiology distinct from tobacco smoke.
Objective 1: Synthesis of the methodologies of Mannino et al., (2003); Shiue,
(2016); and Tilert et al., (2013) to determine if there is a significant association between
PAHs and COPD.
Objective 2: Measure the associations between PAHs and COPD occurrence
among smokers versus non-smokers to assess statistical significance in COPD prevalence
among non-smokers specifically.
Objective 3: Measure the associations between PAHs and lung cancer occurrence
among smokers versus non-smokers to assess statistical significance in lung cancer
prevalence among non-smokers.
Null hypothesis: There is no significant association between PAH levels and
spirometry-confirmed COPD and lung cancer co-occurrence among non-smokers.
Alternative Hypothesis: There is a significant association between PAH levels and
spirometry-confirmed COPD and lung cancer co-occurrence among non-smokers.

Results
Sample Size and Descriptive Statistics
The overall NHANES sample from combined years between 2007 and 2012 was
30,442 respondents. The laboratory sub-sample provided 23,337 serum cotinine
responses. Additional laboratory sub-sampling for PAHs had respective sample sizes
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ranging from 7,735 (1-hydroxynaphthalene) to 7,846 (9 hydroxyflourene). The
spirometry sub-sample consisted of 20,050 responses. Descriptive statistics for the
categorical and continuous variables utilized in the analysis are included in Tables 2.1
and 2.2.
Frequencies for the dependent variables of COPD and lung cancer were as
follows. The number of respondents indicating a medical professional had previously
diagnosed the respondent with COPD was 1,229. It is important to note these were selfreported. The frequency for spirometry-confirmed COPD was 518 with a combined
sample size for self-reported COPD and spirometry-confirmed COPD of 1,690 cases
(adjusted for duplicates). The self-reported lung cancer frequency was 37 cases and thus
was not powerful enough to generate any reliable estimates from a regression analysis
after adjusting for confounders. Finally, smoking was defined as having a serum cotinine
level >13.7 ng/ml, which resulted in a frequency of 4,291 overall smokers in the sample.
Cross tabulations of smoking status by overall COPD, spirometry-confirmed COPD, and
lung cancer frequencies are included in Table 2.3.
Principal Components Analysis
A principle component analysis (PCA) allows for the reduction in the number of
covariates utilized in a multivariate analysis while still accounting for most of the
variance in the observed variables (Abdi & Williams, 2010). To reduce the number of
PAH covariates tested in the logistic regression, a PCA was performed on the nine PAH
log transformed covariates included in the NHANES laboratory sub-sample. It is
important to note additional PAHs are available for certain years of the Continuous
NHANES sample, however only those available across all the three iterations (2007,
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2009, and 2011) of these NHANES years are included. One factor from the PCA resulted
to be significant with an eigenvalue greater than one as well as the results of the scree
plot with significant distance between this factor and the rest of the factors (Cattell,
1966). Table 2.4 provides a summary of the respective eigenvalues of each factor and
figure 2.1, the scree plot of each eigenvalue.
Model 1: Regression Stratified by Age Alone
Two logistic regression models were generated to carry out the objectives described
above. Model 1 stratified by age alone and Model 2 stratified by adult smoking status.
Adults 20 years and above comprised the portion of the sample tested in the first model.
Degrees of freedom (DF) for the logistic regression were set to infinity. Classes for the
categorical variables were set as those with probable healthy effects i.e. gender = female,
race = Caucasian, smoker = no, education = high school diploma or more, etc. The
weight variable employed in the model was derived from the laboratory sub-sample for
PAHs where the rationale for employment of various NHANES weight variables is
dependent upon the smallest sub-sample utilized in the analysis (National Center for
Health Statistics, 2006). Thus, the weight for the PAH sub-sample was utilized since it
was the smallest sub-sample included in the overall dataset. Additionally, stratum and
cluster variables were used according to NHANES analytic and reporting guidelines.
Urinary creatinine was included in the model since other urinary sampling biomarkers
(PAHs) were also used in the model. Creatinine provides for an adjustment effect on the
urinary sample to account for variable dilutions (Barr et al., 2005).
The number of observations used in Model 1 was 2,308. 219 cases for overall COPD
(self-report and spirometry-confirmed COPD) and 2,089 non-COPD cases were included
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in the response profile of the model. Statistically significant covariates were defined as
those with a p-value < 0.05. According to the analysis of maximum likelihood estimates,
the significant covariates identified in the model were “Other” Race (p=0.0012), Smokers
(p<0.0001), Former Smokers (p=0.0348), Secondhand Smoke Exposure in the Home
(p=0.0092), Age (p<0.0001), BMI (p=0.0029), and PAHs (Factor1) (p=0.0098). Table
2.5 provides a summary of the maximum likelihood estimates of all of the covariates
included in the model. The respective odds ratios for the significant covariates were
“Other” Race 0.491 (0.319, 0.756), Smokers 2.314 (1.536, 3.485), Former Smokers 1.482
(1.028, 2.135), Secondhand Smoke Exposure in the Home 1.722 (1.144, 2.592), Age
1.039 (1.026, 1.053), BMI 1.037 (1.013, 1.062), and PAHs (Factor1) 1.295 (1.064,
1.575). Odds ratios for all covariates included in the model are summarized in Table 2.6.
The only odds ratio with a negative correlation/protective effect for COPD was “Other”
Race which included Hispanics as well as various other races. All other statistically
significant odds ratios had positive correlations/non-protective effects, including PAHs.
Model 2: Regression Stratifying by Smoking Status
To further investigate a potential environmental link between PAHs and COPD, a
logistic regression analysis was carried out to isolate the effects of PAHs on COPD from
smoking. Thus, a model was generated stratifying the sample by smoking status. All
specifications for degrees of freedom, weighting, stratum, cluster, and classes were
repeated as in model 1. The domain specified in the model was adults 20 years and above
who were positive for serum cotinine at 13.7 ng/ml or above (smoking biomarker). The
following results were generated in the model among the non-smoking cohort of the
NHANES sample.
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The number of observations read and used in the model were 30,442 and 2,260,
respectively. 90 cases for overall COPD (self-report and spirometry-confirmed COPD)
and 1,360 non-COPD cases were included in the response profile of the model for nonsmoking adults. Three statistically significant covariates were identified in the analysis,
Age (p<0.0001), BMI (p=0.0393), and Alcohol Consumption (p=0.0347). PAHs
(Factor1) had a non-significant estimate (p=0.4828). All statistically significant
covariates had positive correlations/non-protective effects with COPD cases. Table 2.7
includes a summary of all covariates including the Chi Square tests of their respective
estimates. Odds ratios for all covariates are included in Table 2.8. Specifically, the odds
ratio for PAHs (Factor1) was 1.120 (0.816, 1.537).
It is important to note a third model was carried out to explore any additional
statistical significance among PAHs and COPD. This model included all Continuous
NHANES iterations from 2003 to 2014 (n=61,087) where PAHs were collected in the
laboratory sub-sample (PAHs were not collected in 2015 NHANES and 2017 NHANES
is still undergoing data collection). When stratifying for smoking status among these
years, this additional logistic regression analysis did not yield any statistically significant
results among the non-smokers for PAHs (p=0.4276), in spite of a significantly larger
sample size for self-reported COPD cases (n=2,355). It is also of interest that the lung
cancer cohort (positive cases) during this range of years was still not powerful enough to
include in its own regression analysis (n=84).
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Discussion
Previous evidence associating PAHs with adverse respiratory outcomes like COPD is
well-documented (Pauk et al., 2013; L. Yang et al., 2017; Y. Zhang et al., 2017).
Utilizing a nationally representative human sample that collects PAH biomarkers affords
the analytical opportunity to further investigate these associations on a large scale.
Consistent with the findings from (Shiue, 2016), model one’s results are discussed below,
which are then compared with inconsistent findings from model two.
Model one was a general analysis testing for significance between PAHs and
COPD by stratifying by adults 20 years and above, while adjusting for known
confounders i.e. smoking. A significant association between PAHs with combined selfreported COPD and spirometry-confirmed COPD was found (p=0.0098). The odds ratio
for PAHs in model one demonstrated a non-protective effect on COPD with a value
greater than one (1.295) and a confidence interval that did not include one (1.064, 1.575).
The Chi-squared test for smoking (p<.0001) was significant with COPD in addition to an
odds ratio above one as well (2.314 (1.536, 3.485)). Thus, the need to further isolate the
effect of PAH exposure from smoking to investigate a probable environmental source
was warranted. Since PAH exposure is generated from smoking (Department of Health
and Human Services, 2014), the PAH biomarkers in urine metabolites would be expected
to be elevated. Thus, a model that stratified by smoking status would allow for a more
precise understanding of a potential environmental link (i.e. air pollution) between PAHs
and COPD by separating out the contribution of smoking on PAH exposure. It is
important to note that other statistically significant covariates were found during the
analysis (as identified in the results) in model one and are included in Table 2.5.
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Model two stratified by smoking status and tested the significance of PAHs on
COPD among the non-smoking cohort. PAHs were not statistically significant among the
non-smokers (p=0.4828) in model two. The odds ratio for PAHs was 1.12 with a
confidence interval that included one (0.816, 1.537). Thus, the null hypothesis was
supported and the alternative was rejected; where PAHs were not significantly associated
with COPD among non-smokers, while adjusting for known confounders. Other
statistically significant covariates that are important to note for model two include Age
(p=<.0001), BMI (p=0.0393), and alcohol consumption (p=0.0347). The respective odds
ratios for each of these confounders were all above one, demonstrating a non-protective
effect on COPD occurrence (Table 2.8).
The findings from model one support the results generated by Shiue’s study
investigating PAH associations with emphysema, chronic bronchitis, and asthma while
using an NHANES sample. Shiue found significant associations among several
individual PAHs with chronic bronchitis and emphysema, however no significant
associations were found with asthma or other infections that were assessed i.e. hay fever.
The analysis carried out by (Shiue, 2016) did not include additional covariates related to
other smoking measures i.e. former smokers and secondhand smoke exposure. The
advantage of the current study was the inclusion of these two additional confounders, a
larger sample size of six years of data (rather than a single iteration of two years), as well
as the inclusion of spirometry-confirmed COPD as a dependent variable.
In contrast, the next step of the analysis with model two did not support Shiue’s
overall findings when stratifying by smoking status. As individuals who smoke (as well
as former smokers and those exposed to secondhand smoke) are exposed to PAHs
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resulting from the combustion of tobacco, PAHs are released into the surrounding air and
such individuals are subsequently inhaling these compounds. Therefore, to adequately
investigate whether a nationally representative human sample like NHANES has
significant associations of PAHs with COPD to make the case for air pollution as a
potential source, such a model must include stratification by smoking status. Shiue did
not stratify by smoking status in the original study, or at least no mention of this type of
investigation was made.
The findings from both models warrant additional study into the health effects of
PAHs with adverse respiratory outcomes like COPD. Possible explanations for the lack
of significance of PAHs with COPD in model two may be related to the omission of BaP
as a PAH collected in the NHANES sample, lag time between dose and response from
something like air pollution where exposure levels have decreased, in addition to other
confounding factors not included in the model i.e. potential biomarkers for PM2.5, etc. It
is important to note the additional smoking-related covariates (Former Smokers and
Second Smoke Exposure) could be included in the stratification with overall smokers,
which may have an impact on the strength of association of PAHs in the new model.
Thus, additional modeling with other air pollution-related covariates e.g. PM2.5
biomarkers, as well as adjusting the stratification for additional smoking covariates may
exhibit new results.
Additionally, the work of Alshaarawy, Elbaz, & Andrew (2016) investigated the
association of urinary PAHs with cardiovascular diseases (CVD - stroke, heart attacks,
angina, and coronary heart disease) using an NHANES sample (2001 to 2010). The
pathogenic pathway between oxidative stress, inflammation, and atherosclerosis are well-
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documented (Curfs et al., 2005; Jeng et al., 2011) and provide a biological mechanism for
their analysis’ rationale. Alshaarawy et al. (2016) stratified a multivariate model by
smoking status (former, never, and recently active) using structural equation modeling
and revealed statistically significant findings with PAHs and CVD. Thus, novel
approaches to investigating the role of PAHs on a host of chronic diseases from a known
environmental source like air pollution is warranted in addition to employing similar
statistical techniques like structural equation modeling as proposed by Alshaarawy and
colleagues.
Strengths and limitations
The strength of this study comes in the form of utilizing various biomarkers as
covariates as well as a standardized clinical diagnostic test to generate a dependent
variable with improved precision to test in a multivariate logistic regression model. The
power of the sample was significant using multiple years from NHANES, a nationally
representative sample for human health. Stratification among the non-smoking cohort of
the sample in addition to including several other smoking-related covariates was an
improvement based on a previous study investigating a similar research question. Again,
this was essential to make a stronger case for a potential environmental source of adverse
outcomes related to PAH exposure beyond the influence of individual smoking or
environmental tobacco smoke exposure.
The limitations of the study are related to the cross-sectional nature of NHANES.
Causality was not possible to assess between PAH exposure as a type of dose and COPD
as its response. Next, various other covariates including known biomarkers for air
pollution or other environmental hazards were not pursued in the study as other forms of
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confounders. Specifically, since BaP is not included in the suite of PAHs collected in the
NHANES sample, yet this primary PAH is the most widely studied PAH for its health
effects. Furthermore, BaP specifically has been identified in the pathogenesis with both
COPD and lung cancer (DHHS, 2014; Yang et al., 2017) yet was unfortunately not
possible to test. Finally, the size of the lung cancer sample was not robust enough to test
for significance with PAHs while adjusting for confounders. This may be due to the high
mortality rate related to lung cancer in addition to the increased severity of symptoms that
lung cancer patients endure; which would make them ineligible for participating in each
of the assessments carried out according to the NHANES data collection methodology.
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Table 2.1 Descriptive statistics of NHANES categorical variables used in the logistic
regression analysis (2007-2012 NHANES).a
Frequency

%

Cumulative

Cumulative

Frequency

%

Gender
Male

15,177 49.9

15,177

49.86

Female

15,265 50.1

30,442

100

11,508 37.8

11,508

37.8

6,851 22.5

18,359

60.31

12,083 39.7

30,442

100

Race
Caucasian
African American
Other

2nd Hand Smoke Exposure (home)
No

27,804 91.3

27,804

91.33

Yes

2,638 8.67

30,442

100

Former Smoker
No

26,181

86

26,181

86

Yes

4,261

14

30,442

100

No

17,895 83.7

21,381

100

Yes

3,486 16.3

3,486

16.3

No

12,717 71.9

12,717

71.9

Yes

4,969 28.1

17,686

100

Routine Physical Activity

Some High School or Less

a

All frequencies are un-weighted.
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Table 2.2 Descriptive statistics of NHANES continuous variables used in the logistic
regression analysis (2007-2012 NHANES).a
Variable

Label

N

N
Miss.

Mean

Std.

Min.

Max.

-

4.4073

Dev.
Factor1

Principal

7,347

23,095 2.53E-16 1

Component

2.8172

of logPAHs
Age

Age at

30,442

0

32.3387

25.0055

0

80

26,875

3567

25.6651

7.6921

12.4

84.87

10,305

20137

2.9646

3.1137

1

83

7,907

22535

123.252

79.0192

4

800

Screening
Adjudicate
d - Recode
BMI

Body Mass
Index
(kg/m**2)

Alcohol

Avg #
alcoholic
drinks/day past 12 mos

a

URXUC

Urinary

R

creatinine

6

All frequencies are un-weighted.
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Table 2.3 Cross tabulations of overall COPD (self-reported COPD and spirometryconfirmed COPD), spirometry-confirmed COPD, and lung cancer by smoking status
(2007-2012 NHANES).a,b

Overall COPD - No

Smoker - No

Smoker - Yes

Total

8,034 (63.53%)

3,288 (26%)

11,322
(89.53%)

Overall COPD - Yes

672 (5.31%)

652 (5.16%)

1,324 (10.47%)

Total

8,706 (68.84%)

3,940 (31.16%)

12,646 (100%)

Spirometry-

550 (46.53%)

217 (18.36%)

767 (64.89%)

185 (15.65%)

230 (19.46%)

415 (35.11%)

Total

735 (62.18%)

447 (37.82%)

1,182 (100%)

Lung Cancer - No

763 (71.85%)

278 (26.18%)

1,041 (98.02%)

Lung Cancer - Yes

17 (1.60%)

4 (0.38%)

21 (1.98%)

Total

780 (73.45%)

282 (26.55%)

1,062 (100%)

confirmed COPD No
Spirometryconfirmed COPD Yes

a

All frequencies are un-weighted.

b

Percentages are overall percentages.
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Table 2.4 Eigenvalues from the principal component analysis of the log transformed
PAHs (2007-2012 NHANES).
Eigenvalues of the correlation matrix:
Total = 9 Average = 1
Eigenvalue

Difference Proportion Cumulative

1

6.81091393

6.0910945

0.7568

0.7568

2

0.71981946

0.2592624

0.08

0.8367

3

0.46055711

0.1064763

0.0512

0.8879

4

0.3540808

0.0728273

0.0393

0.9273

5

0.28125353

0.1307852

0.0313

0.9585

6

0.15046834

0.0458525

0.0167

0.9752

7

0.1046158

0.0178218

0.0116

0.9869

8

0.08679403

0.055297

0.0096

0.9965

9

0.031497

0.0035

1.0000
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Figure 2.1 Scree plot of Eigenvalues from principal components analysis of log
transformed PAHs (2007-2012 NHANES).
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Table 2.5 Point estimates and p-values for all variables in model one (2007-2012
NHANES).
Parameter

Estimate

Intercept

Standard

Wald Chi-

Pr > ChiSq

Error

Square

-5.5473

0.5627

97.1937

<.0001

Gender

1

0.2918

0.1725

2.8614

0.0907

Race

2

-0.3451

0.2239

2.3759

0.1232

Race

3

-0.7114

0.2202

10.432

0.0012

Smoker

1

0.839

0.209

16.1199

<.0001

Former Smok

1

0.3933

0.1863

4.4547

0.0348

HomSmokExp 1

0.5432

0.2087

6.7761

0.0092

0.029

0.1999

0.021

0.8848

Age

0.0386

0.00644

35.8265

<.0001

BMI

0.0364

0.0122

8.8867

0.0029

Alcohol

0.0296

0.0309

0.9172

0.3382

Creatinine

-0.00292

0.00182

2.5681

0.109

PAHs (all)

0.2584

0.1

6.6772

0.0098

Some HS or

1

less
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Table 2.6 Odds ratio estimates for model one (2007-2012 NHANES).
Effect

Point

95% Wald Confidence

Estimate

Limits

Gender 1 vs 2

1.339

0.955

1.877

Race 2 vs 1

0.708

0.457

1.098

Race 3 vs 1

0.491

0.319

0.756

Smoker 1 vs 0

2.314

1.536

3.485

FormSmok 1 vs 0

1.482

1.028

2.135

HomSmokExp

1.722

1.144

2.592

1.029

0.696

1.523

Age

1.039

1.026

1.053

BMI

1.037

1.013

1.062

1.03

0.969

1.094

Creatinine

0.997

0.994

1.001

PAHs (all)

1.295

1.064

1.575

1 vs 0
Some HS or less
1 vs 0

Alcohol
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Table 2.7 Point estimates and p-values for all variables in model two (2007-2012
NHANES).a
Parameter

Estimate Standard
Error

Intercept

Wald Chi-

Pr > ChiSq

Square

-6.1678

0.8236

56.0773

<.0001

Gender

1

0.1703

0.3491

0.238

0.6256

Race

2

-0.0591

0.3376

0.0307

0.861

Race

3

-0.6022

0.3216

3.5056

0.0612

FormSmok

1

0.4451

0.2403

3.431

0.064

HomSmokExp 1

0.1988

0.5388

0.1361

0.7122

-0.2753

0.3551

0.6011

0.4381

Age

0.0386

0.00774

24.8602

<.0001

BMI

0.0382

0.0185

4.2479

0.0393

Alcohol

0.0928

0.0439

4.458

0.0347

Creatinine

0.00101

0.00234

0.1853

0.6668

PAHs (all)

0.1133

0.1614

0.4925

0.4828

Some HS or

1

less

a

Model estimates are reported for the non-smoking sub-sample.
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Table 2.8 Odds ratio estimates for model two (2007-2012 NHANES).a
Effect

Point

95% Wald Confidence

Estimate

Limits

Gender 1 vs 2

1.186

0.598

2.35

Race 2 vs 1

0.943

0.486

1.827

Race 3 vs 1

0.548

0.292

1.029

FormSmok 1 vs 0

1.561

0.974

2.499

1.22

0.424

3.507

0.759

0.379

1.523

Age

1.039

1.024

1.055

BMI

1.039

1.002

1.077

Alcohol

1.097

1.007

1.196

Creatinine

1.001

0.996

1.006

PAHs (all)

1.12

0.816

1.537

HomSmokExp
1 vs 0
Some HS or less
1 vs 0

a

Model estimates are reported for the non-smoking sub-sample.
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Table 2.9 Point estimates and p-values of individual PAHs from model one (2007-2012
NHANES).a
Parameter

a

DF Estimate Standard Wald
Error
Chi-Square
0.0497
7.9316

Pr > ChiSq

1-napthol

1

0.1398

0.0049

2-napthol

1

0.1047

0.0848

1.5272

0.2165

3-fluorene

1

0.1417

0.0834

2.8874

0.0893

2-fluorene

1

0.2288

0.0873

6.8756

0.0087

3-phenanthrene

1

0.1538

0.0808

3.6287

0.0568

1-phenanthrene

1

0.1192

0.0874

1.8629

0.1723

2-phenanthrene

1

0.1792

0.0789

5.1621

0.0231

1-pyrene

1

0.0835

0.0668

1.5609

0.2115

Covariates for model one were included in the analysis but are not reported.
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Table 2.10 Odds ratio estimates for individual PAHs in model one (2007-2012
NHANES).a
Effect

a

Point Estimate 95% Wald
Confidence Limits
1.043
1.268

1-napthol

1.150

2-napthol

1.110

0.940

1.311

3-fluorene

1.152

0.978

1.357

2-fluorene

1.257

1.059

1.492

3-phenanthrene

1.166

0.996

1.366

1-phenanthrene

1.127

0.949

1.337

2-phenanthrene

1.196

1.025

1.396

1-pyrene

1.087

0.954

1.239

Covariates for model one were included in the analysis but are not reported.
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Table 2.11 Point estimates and p-values of individual PAHs from model two (2007-2012
NHANES).a,b
Parameter

a

DF Estimate Standard Wald
Error
Chi-Square
0.0751
1.6173

Pr > ChiSq

1-napthol

1

0.0956

0.2035

2-napthol

1

-0.1382

0.1080

1.6383

0.2006

3-fluorene

1

-0.0430

0.1191

0.1306

0.7178

2-fluorene

1

0.0544

0.1055

0.2659

0.6061

3-phenanthrene

1

0.0350

0.1200

0.0850

0.7706

1-phenanthrene

1

0.0178

0.1009

0.0310

0.8603

2-phenanthrene

1

-0.0574

0.1007

0.3251

0.5686

1-pyrene

1

-0.0721

0.0864

0.6958

0.4042

Covariates for model two were included in the analysis but are not reported.

b

Estimates are reported for the non-smoking sub-sample.
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Table 2.12 Odds ratio estimates for individual PAHs in model two (2007-2012
NHANES).a
Effect

a

Point Estimate 95% Wald
Confidence Limits
0.950
1.275

1-napthol

1.100

2-napthol

0.871

0.705

1.076

3-fluorene

0.958

0.758

1.210

2-fluorene

1.056

0.859

1.298

3-phenanthrene

1.036

0.819

1.310

1-phenanthrene

1.018

0.835

1.241

2-phenanthrene

0.944

0.775

1.150

1-pyrene

0.930

0.786

1.102

Model estimates are reported for the non-smoking sub-sample.
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CHAPTER 3
ESTIMATING THE STRENGTH OF ASSOCIATION AMONG COPD
AND LUNG CANCER DEATHS ATTRIBUTABLE TO PAHS IN SOUTH
CAROLINA
Overview
The scope of the investigation for chapter three was a state-wide population-based
ecological study of PAH exposure concentrations in South Carolina. It sought to test the
strength of PAH associations with deaths from COPD and lung cancer. In other words,
this population-based ecological study assessed annual PAH exposure concentrations and
to what extent they contribute to mortality from the two diseases.
The rates of COPD mortality and morbidity in SC rank among the highest in the
nation. COPD prevalence among South Carolinians ranked 15th in the nation (within the
highest quartile) in 2016 with an age-adjusted prevalence of 7.1% (Centers for Disease
Control and Prevention, National Center for Chronic Disease Prevention and Health
Promotion, Division of Population Health, 2016). Additionally, COPD is the fourth
leading cause of death in SC and SC had the 12th highest mortality rate from COPD in the
nation in 2017 (Centers for Disease Control and Prevention, National Center for Health
Statistics, 2017). In regards to lung cancer, South Carolina ranks 17th in age-adjusted
incidence (64.2 cases/100,000 people in 2014), and 18th for age-adjusted mortality (46.6
deaths/100,000 in 2014) (U.S. Cancer Statistics Working Group, 2017).
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A significant proportion of COPD and lung cancer cases are attributable to smoking both
nationally as well as in SC (DHHS, 2014; McLain et al., 2017). This was an important
investigation from a state-wide perspective to assess what
proportion of these diseases can be attributed to an exposure hazard beyond that of
tobacco smoke. Additionally, the connection of this study to the port expansion in
Charleston speaks to the importance of estimating the influence of a new context of
ambient air pollution for the state.
The main research question of chapter three was whether there exists a significant
association between deaths from COPD/lung cancer given the annual exposure
concentrations of PAHs at the census tract level. The primary hypothesis to test was
whether environmental exposure to ambient PAHs significantly contributes to mortality
from the two diseases. It is important to note that although a significant section of the
literature review was devoted to the etiopathogenesis of COPD-lung cancer from PAHs,
it was beyond the scope of this investigation to determine whether ambient PAH
exposures caused the deaths from COPD or lung cancer in the study population.
Estimating attributable mortality to PAHs was the scope of the study’s investigation.
Finally, two primary data sources were used to test the hypothesis referenced
above. The first was the EPA’s National Air Toxics Assessment (NATA) datasets for
years 2002, 2005, and 2014. The rationale for employing this source in the study is
addressed below. The second primary dataset employed was mortality data for South
Carolina, provided in five year aggregates between 2002 and 2014. The source for this
data was the SC Department of Health and Environmental Control’s Office of Vital
Statistics (DHEC VS).
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Study Rationale
Numerous air pollution studies assessing adverse health outcomes (i.e. mortality)
used approaches similar to the one outlined in this chapter. Additionally, one of the most
relevant studies identified in chapter one, the ESCALA study, assessed daily air pollution
concentrations and the effect on mortality in nine Latin American cities (Romieu et al.,
2012). In it, COPD was identified to have significant mortality effects from daily air
pollution concentrations. While daily concentrations are not assessed by EPA within
NATA, studies utilizing annual concentrations are of significant importance to build an
evidence-base to justify the proposed study, and are summarized below.
Numerous investigations were identified in the literature that used annual air
pollution concentrations to assess the contribution to adverse health outcomes. In this
respect, annual concentrations of air pollutants were most commonly referred to as long
term exposure assessments (vs. short-term or daily assessments) in the identified studies.
The most common air pollutants identified in the literature included PM10, PM2.5, NO2,
SO2, NOx, and O3. Two significant studies assessed lung cancer mortality using annual
ambient air quality data, Hwang, Lee, Jung, Lim, & Kwon (2007) and Sifaki-Pistolla et
al. (2017). Hwang et al., (2007) utilized a Poisson model to analyze annual ambient air
quality data with standardized mortality ratios (SMRs) and standardized incidence ratios
(SIRs) from national cause of death statistics in seven South Korean cities. They found
significant associations with PM10 and lung cancer mortality among females. SifakiPistolla et al. (2017) carried out a lung cancer mortality and incidence study in Greece
that used annual concentrations of air pollutants and matched these to mortality rates and
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age-adjusted incidence from the national cancer registry. A significant association was
found between ambient air pollutants and lung cancer mortality, with the highest risk
found in major urban centers.
An additional study that used a similar approach was carried out by Cao et al.
(2011). In their investigation, a cohort of middle-aged men and women (N=70,947) were
followed up after 10 years to assess mortality. They matched national hypertension
survey data with fixed-site monitor data using resident zip codes. Their findings showed
similar results from above with statistically significant associations of SO2 and NOx with
cardiopulmonary and lung cancer mortalities. Additional studies using annual
concentrations of hazardous air pollutants (HAPs) to assess mortality and other adverse
outcomes include Yorifuji et al. (2013), Orru, Laukaitienė, & Zurlytė (2012), Elliott,
Shaddick, Wakefield, de Hoogh, & Briggs (2007), Chiu et al. (2006), Jiřík et al. (2016),
Gholampour et al. (2014), and Nasser et al. (2015).
Modeling air quality exposures has precedence in epidemiological studies such as
Carey et al. (2013), Bentayeb et al. (2015), and Thurston et al. (2016). Specifically, Carey
et al. (2013) was an English cohort study that used annual pollution concentrations
(PM10, PM2.5, NO2, O3, & SO2) and emissions-based models to match with death
certificates at the postcode level. Bentayeb et al. (2015) was a French cohort mortality
study and used a chem-transport model to estimate annual pollution exposures of PM10,
PM2.5, NO2, O3, and SO2. Finally, Thurston et al. (2016) was a large U.S. cohort
mortality study (N=517,041 men and women) that used annual exposure estimates
derived from EPA’s Air Quality System (AQS) to generate census tract level estimates of
PM2.5.
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The use of NATA exposure concentrations of various HAPs is well documented
in the epidemiological literature. Many of them have focused on the early childhood
impacts of various ambient air pollutants. Perhaps one of the most relevant studies to the
proposed research was the work of Grineski & Collins (2018). They used NATA data to
assess environmental justice issues of neurotoxicants in U.S. public schools. Their most
significant findings revealed that Metropolitan New York public schools (EPA Region 2)
were identified as the most burdened from ambient neurotoxicants in the country
(Metropolitan New York is the study area of chapter four’s analysis). Additional studies
using NATA’s annual ambient exposure concentrations include Lupo et al. (2010),
Stingone, McVeigh, & Claudio (2017), Dickerson et al. (2016), Woodruff, Wells, Holt,
Burgin, & Axelrad (2007), and Windham, Zhang, Gunier, Croen, & Grether (2006).
By proposing the use of NATA’s modeled approach to include in a new model to
regress ambient PAH contributions with COPD and lung cancer death in South Carolina
(as well as in New York City), there is an inherent limitation that models upon models
add to the overall noise or uncertainty of overall estimates. As demonstrated above, this
has not been a deterrent to utilizing NATA in epidemiological studies as a reliable data
source to assess the adverse health outcomes from hazardous environmental exposures
previously. Given this potential limitation however, there is documented literature of
NATA’s sensitivity analyses. Touma, Isakov, Ching, & Seigneur (2006) provide a
general overview of NATA by summarizing its strengths and applications while
addressing its limitations. They point out that model-to-monitor comparison of NATA’s
ambient concentration estimates that were modeled, performed within a factor of two at
most sites. Dominici, Zeger, & Samet (2000) indicate that personal exposure assessment
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reveals that pollutant monitors aren’t enough. Thus, quality personal exposure considers
both indoor and outdoor sources for exposures. Payne-Sturges, Burke, Breysse, DienerWest, & Buckley (2004) add to this with their sensitivity study using a NATA model
while comparing it to personal exposure monitoring efforts. Their rationale for this study
indicated that human exposure research has consistently shown personal exposures can
be significantly different from outdoor air concentrations. Thus, risk assessments using
such sources can over or under-estimate risk. Their results revealed that NATA’s related
model was reasonably accurate as a surrogate for personal exposures when it came to
mobile sources and background sources. In other areas, it estimated lower exposures.
When this was extrapolated for lifetime cancer risk for example, there was a three-fold
greater estimate than that of what NATA estimated. The authors continued here on the
importance of considering indoor sources for personal exposure, which when accounting
for indoor secondhand smoke exposure, would most likely assume a significant
proportion of HAP exposure.
EPA NATA Overview and Methodology
Assessment of the PAH exposure concentration amounts at the census tract level
over the course of a given year are based on the EPA’s hybrid model used to develop this
respective variable in the National Air Toxics Assessment (NATA) dataset. The rest of
the section below is devoted to providing a summary of the methodology used to develop
the exposure concentration variable.
Before summarizing how population exposures are estimated within NATA, it is
important to identify the larger methodology EPA carried out to generate the overall
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dataset. There are four primary analytical steps taken to complete each iteration of
NATA:
•

Compile National Emissions Inventory (NEI);

•

Estimate ambient concentrations of air toxics across the U.S;

•

Estimate population exposures; and

•

Characterize potential public health risks from inhalation.

The current study was interested in the first three steps identified above and
completed its own investigation of the public health risks associated with estimated
exposures. The bulk of this current section will summarize the hybrid model used to
generate population exposure estimates, while briefly touching upon the first step
identified above to provide a basic foundation of the overall NATA methodology.
The NEI provides the basis for which NATA emissions are assessed, where the
methodology for its collection has been described elsewhere (Environmental Protection
Agency Office of Air Quality, Planning, and Standards, 2016). The approach taken
within NATA is to systematically compile a nationwide inventory of air toxic emissions
with NEI as its primary source. Quality assurance and reviews were conducted by state
and local agencies as well as reviewers to make changes while the NATA emissions
inventory was in development. To process the NEI data, certain steps took place such as
placing individual chemicals into groups as well as adjusting emission rates of metal
compounds based on the molecular weights of toxic metal proportions found within it
(Environmental Protection Agency Office of Air Quality, Planning, and Standards, 2015).
NATA includes the following emission source types and estimates from NEI:
•

Point sources/Major Stationary Sources i.e. factories, large waste incinerators, etc;
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•

Nonpoint sources/area and smaller stationary sources i.e. small manufacturers, dry
cleaners;

•

On-road and non-road mobile sources i.e. trucks, cars, boats, etc;

•

Fires and biogenic sources;

•

Estimates for background emissions from natural and anthropogenic toxics
persisting from previous emission years as well as those transported from distant
sources;

•

Estimates for secondarily formed emissions i.e. photochemical reactions in the
atmosphere producing formaldehyde, acrolein, etc.

NEI data sources for HAPs used to develop NATA emissions have been described
elsewhere. A full description of the first analytical step in the NATA methodology of
compiling NEI emissions data can be accessed in the NATA Technical Support
Document (TSD) found at: https://www.epa.gov/national-air-toxics-assessment/2011nata-technical-support-document).
Each iteration of the NATA dataset (1996, 1999, 2002, 2005, 2011 and 2014)
included improvements in their air quality and exposure modeling. The latest
methodology from 2014 will be covered below and areas where the previous iterations of
the methodology were improved upon will be addressed where appropriate.
A hybrid approach was used by the EPA to generate census tract-level air quality
concentrations of air toxics within NATA. The two models used during this analytical
step were the AERMOD dispersion model (American Meteorological
Society/Environmental Protection Agency Regulatory Model - a component of the
Human Exposure Model version 3; HEM-3) and a chemical transport model, CMAQ (the
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Community Multiscale Air Quality Modeling System). Both were utilized within NATA
to capitalize on their individual strengths.
CMAQ’s function as a model is to carry out urban and regional scale simulations
of multiple air quality issues (Environmental Protection Agency Office of Air Quality,
Planning, and Standards, 2015). Its novel technique brings together both physical and
chemical purposes connected to air pollutants at various scales and how they are
transported and dispersed. The resolution of the grid used by CMAQ to generate ambient
air concentrations was 12 km x 12 km. Primary abilities of the CMAQ model that are
considered strengths include conservation of mass (accounts for pollutants leaving an
area and its contribution to the new area), consideration of long range transport of
pollutants, and estimated concentrations of secondarily-formed pollutants. A total of 40
HAPs are modeled in CMAQ and its uniqueness in comparison to AERMOD is its
inclusion of fires and biogenic emissions as well as the secondary formation of pollutants.
Neither of these were included in AERMOD.
AERMOD is the EPA’s preferred air quality model used for regulatory purposes.
It has the ability to estimate ambient concentrations at a low geographic granularity.
During the analysis, AERMOD was run within the larger HEM-3 model (specifics of the
HEM-3 can be accessed in the TSD). According to the NATA Technical Support
Document, the AERMOD receptor locations used during the modeling were based on
three primary elements: centroid of populated census blocks, monitoring site positions,
and five evenly distributed points within each 12 km x 12 km CMAQ grid cell. The
concentrations for each census block were then weighted according to population size to
develop census tract concentrations. Again, the differences between AERMOD and
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CMAQ were with fires and background estimates only being addressed by CMAQ.
However, AERMOD did include all of the other emission source types. The final output
of AERMOD provides ambient air concentrations for each receptor.
The hybrid approach of both models entailed capitalizing on the low geographic
granularity of pollution sources from AERMOD with the contribution of the chemistry
and transport provided by CMAQ. It is important to note that AERMOD as a model does
not treat pollutant species as chemically reactive. Therefore, the data from emissions and
meteorology used in CMAQ were taken an additional step to align AERMOD inputs with
that of CMAQ. The EPA suggests that the novelty of this hybrid approach to modeling
“attempts to optimize characterization of non-reactive and reactive species across
multiple spatial scales” (Environmental Protection Agency Office of Air Quality,
Planning, and Standards, 2015 p.81). The advantage of this approach compared to the
modeling carried out in 2005 is the capability to “anchor” the AERMOD receptor
concentrations to the CMAQ grid concentrations. Without such an approach, mass is not
conserved and double counting can take place to create redundancies, which was a
limitation in 2005’s model.
Background estimates of ambient air toxics is an important consideration
accounted for within NATA. Background concentrations considered were those from
natural sources, emissions of persistent chemicals occurring from the previous year, and
long-range transport from distant sources. These are treated separate from anthropogenic
emissions of the same pollutants for a given year. The modeling carried out by CMAQ
included background concentrations while a spatially uniform remote background
concentration was calculated for the AERMOD-only pollutants and added to the overall
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model concentrations. The final output from the hybrid model estimates ambient
concentrations at every census block receptor which was then weighted according to the
block’s population to generate a population-weighted average across the respective
census tract.
NATA used an additional model to assess human exposure to ambient
concentrations at the census tract level called, HAPEM7. This next analytical step in
NATA’s methodology is imperative as the concentration of a pollutant that a human
breathes could be higher or lower than the ambient concentration of a fixed location, in
this case estimated for census tracts (Environmental Protection Agency Office of Air
Quality, Planning, and Standards, 2015). Additionally, both AERMOD and CMAQ do
not directly address this level of human exposure in their respective models. Thus,
HAPEM7 utilized the ambient concentrations of census tracts estimated from the hybrid
approach as inputs in for its model, which is termed a screening-level inhalation exposure
model.
Alongside ambient concentrations, HAPEM7 used a series of inputs from a
variety of sources to generate estimates for human exposure. Sources include census data,
human activity pattern data, ambient air quality levels, climate data, and indoor/outdoor
concentration relationships. What is then estimated at this point in the analysis is an
expected range of inhalation exposure concentrations for groups of individuals. Then, for
the best estimate of exposure, the estimate is derived for a hypothetical person for the
respective census tract.
It is important to note that the analyses in the 2002 and 2005 NATA datasets
employed the HAPEM simulation generated in 1999 while the 2011 and 2014 NATA
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used a combination of new updates with the original model. These new simulations were
carried out for a variety of pollutants which included generic PAHs – of primary interest
for chapter three’s investigation. 41 HAPS and diesel PM were estimated in 2011, while
51 HAPS and diesel PM were estimated in 2014.
Again, additional analytical detail for estimating population exposures is provided
in the NATA TSD. Background for the HAPEM7 model can be found at the following
weblink: (https://www.epa.gov/fera/human-exposure-modeling-hazardous-air-pollutantexposure-model-hapem). Finally, it is important to note that various other approaches to
modeling within NATA were carried out in previous iterations of the assessment system.
According to the Environmental Protection Agency Office of Air Quality, Planning, and
Standards (2015), a series of changes made to modeling ambient concentrations as well
as exposure estimates vary across each iteration. Additionally, the final step of estimating
health risks within NATA is not expounded upon here as it does not pertain to the current
study since that is the scope of this analysis.

Methods
Again, chapter three is an investigation in the association of COPD and lung
cancer deaths with PAHs from outdoor air using South Carolina as the study area. The
primary statistical procedure used for this analysis was a Poisson regression model since
its focus was modeling using counts of which census tract mortality aggregates were
analyzed. Two models were developed, one for COPD and another for lung cancer. As
was used in chapter two, SAS 9.4 was the primary statistical software utilized to run the
analysis.
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Air Quality data for PAH exposure concentrations were acquired from the EPA’s
National Air Toxics Assessment (NATA) data portal for the following years: 2002, 2005,
and 2014. Although 2011 NATA was available for use and was assessed in the analysis
for the 2010-2014 models for lung cancer and COPD, only the 2014 results are presented
since they are the most recent. Additionally, no significant differences were observed
between the two iterations in the 2010-2014 models. Next, although earlier years of
NATA were available for 1996 and 1999, EPA did not model annual PAH exposure
concentrations at the census tract level during these two first iterations. Finally, NATA
datasets are public domain and require no payment to download.
Mortality data for COPD and lung cancer were acquired from DHEC VS and
were provided in five-year aggregates of mortality frequencies for the above diseases in
each census tract across the state. A data request was completed to acquire mortality data
from DHEC VS according to agency protocol. A concurrent proposal was submitted
through the University of South Carolina’s Office of Research eIRB portal acquiring IRB
approval to satisfy institutional review of the study. ICD-10 codes requested from DHEC
Vital Statistics included J40-J44 and J47 for COPD and C34.82, C34.90, and C34.91 for
lung cancer.
Various other data sources were utilized to carry-out the modeling in the study.
These sources and the justification for testing in the Poisson models for each disease are
addressed in the next section. All data were matched at the census tract level in an
attempt to acquire the same geographic comparisons, where available. Variables available
at the county level as the lowest level of geographic granularity are indicated in the
following section as well. Years of all covariates/independent variables matched with the
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dependent variable of COPD and lung cancer deaths were analyzed where available
among the years between 2002 and 2014.
COPD Model Covariates
Specific covariates for deaths related to COPD and lung cancer vary, thus the
need for two distinct Poisson models. To isolate the associated significance of PAH
exposure concentrations with COPD/lung cancer mortalities, adjustment of confounding
factors were carried out by including a variety of covariates into the model.
Schembri et al. (2009) developed a predictive model for COPD hospital
admissions and deaths assessing numerous explanatory variables including gender, age,
smoking status, BMI, respiratory symptoms (spirometry, dyspnea score, mobility, airway
questionnaire, etc.), and past medical history (oxygen use, inhaler technique, steroid use,
antibiotic use, and vaccination status). Additionally, a review by Celli (2010) reported
primary predictors of COPD mortality such as Forced Expiratory Volume in one second
(FEV1), dyspnea, exercise capacity, and BMI.
Several studies have assessed the causes of mortality in COPD. For example, the
Lung Health Study carried out a randomized clinical trial (RCT) among smokers aged 35
- 60 using cessation treatments as well as bronchodilator therapy. Mortality rates were
low (12% among the cohort), however the leading causes of death during the 14-year
follow-up were cancer (33%), cardiovascular disease (22%), and respiratory disease (8%)
(Anthonisen et al., 2005b). Another study among more severe cases of COPD revealed
different results. Among patients with COPD where inhaled corticosteroids and a
placebo were used for treatment, a pooled analysis of RCTs demonstrated that during a
follow-up period of 26 months, the leading causes of death included respiratory disease
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(34%), cardiovascular disease (30%), cancer (21%) and other causes (15%) (Sin et al.,
2005).
Given these predictors of COPD mortality were primarily focused on individual
medical histories, it is a known limitation for an ecological study like the one outlined
above that relies on population data to adequately predict COPD deaths from PAHs
without access to direct medical records where variables like FEV1, BMI, comorbidities,
oxygen use, etc. could be assessed for inclusion into a predictive model. However, since
this is a population-based study, the following variables will be relied upon. With this
ecological approach, covariates will be socio-economic (census-sourced) and
environmentally focused. Furthermore, there is substantial public and population health
evidence for such statistical modeling with support from frameworks like the social
determinants of health and conceptual frameworks that link population with elements like
primary health care service (Levene, Bankart, Khunti, & Baker, 2012; Singh et al., 2017).
Several studies have assessed socio-economic and environmental factors for
COPD mortality at the population level. Levene et al., (2012) carried out a mortality
study for various chronic diseases investigating primary care centers. The main predictors
for mortality in the study were age and low socio-economic status (SES). In regards to
access to medical care, a 1% increase in the proportion of patients recalling better able to
see their preferred doctor was associated with reductions in COPD mortality by 0.7% (CI
0.2-2.0%, p=0.02). Gershon, Dolmage, Stephenson, & Jackson (2012) carried out a
review of the most significant determinants of health for COPD outcomes with a specific
focus on socio-economic status. Specific findings suggested that COPD sufferers of the
lowest SES bracket were twice as likely to have poor outcomes when compared to the
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highest bracket. They conclude that social and economic disadvantage has a consistent
and significant effect on both mortality and morbidity from COPD.
The primary data source that was used to assess SES-related covariates in the
COPD-Poisson model was the American Community Survey (ACS) and 2000/2010
census results found on the American Fact Finder web portal
(https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml). ACS covariates were
accessed using census tract geographies and linked with the NATA-PAH and DHEC VSCOPD mortality datasets (also outlined for census tract counts). Age, race/ethnicity,
gender, educational attainment, employment status, median household income , and
poverty status in the past 12 months were covariates acquired from ACS/census.
Environmental or ecological predictors of mortality can be construed from a
broad lens in public and population health; however, classical environmental domains
would consider covariates from air, water, and soil sources. Thus, the NATA-PAH
dataset was the primary source for air to be assessed in the model. County-level smoking
prevalence was included using BRFSS five year moving averages available from the
Robert Wood Johnson County Health Rankings.
A primary climate-related variable included in one of the short-term/daily air
pollution studies addressed above, included temperature as a statistically significant
covariate (Romieu et al., 2012). From a long-term investigative approach using annual
ambient concentration exposures matched with annual mortalities, the overall sample size
of temperature on a yearly frequency was assumed to be too small for significance for
inclusion in the model. Thus, accommodation was pursued by other means by
aggregating the number of temperature related events in a given year by using National
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Oceanic Atmospheric Administration (NOAA) 30-year averages for the number of
heating and cooling days.
Offering evidence for which environmental covariates (i.e. temperature) to test in
the model is the work of Chan, Weinhold, Thomas, Gohlke, & Portier (2015). They
tested the environmental predictors for mortalities related to cardiopulmonary and
cardiovascular diseases across all counties in the U.S. including COPD and lung cancer.
Primary climate-related data utilized by Chan et al. (2015) include monthly averages of
three primary determinants of weather: temperature, precipitation, total heating degree
days and total cooling degree days. The U.S. National Oceanic and Atmospheric
Administration’s Comparative Climatic Data was used as the source for this data. Also
included were air quality concentrations of NOx, SOx, PM2.5, PM10, Volatile Organic
Carbons (VOCs), NH3, CO, and O3 that came from a variety of EPA sources. Another
air quality measure included was diesel emissions which was acquired directly from
NATA. Socio-economic data tested in their model included social capital data derived by
Rupasingha, Goetz, & Freshwater (2006). They used 14 county-level social capitalrelated indicators which were assessed and merged into five components e.g. community
organizational life, engagement in public affairs, social trust, etc. These were used by
Chan et al. (2015) to generate a total of 16 social capital indicators that were tested in
their analysis. Also included were risk factor data on exercise, few fruits and vegetables,
obesity, hypertension, smoking, and diabetes, which were acquired from the U.S.
Department of Health and Human Services’ Community Health Status Indicators.
Finally, demographic and economic-related data was sourced from the Census Bureau
including poverty level, educational level, number of primary care physicians per 10,000
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population, number of dentists per 10,000 population, racial composition, median ages
for each sex, combination of both sexes, median household income, median family
income, county per capita income, crime characteristics, housing characteristics, and
employment by industry.
The results from Chan et al. (2015) for all-causes mortality revealed only two
statistically significant predictors across all groups. These were percentage of single
parent households and percentage of people aged 16-64 years with physical disability.
Among four of the groups, percentage of votes cast for president, percentage of Hispanic
or Latino, percentage of adults reporting no exercise, and total suicide deaths per 100,000
population were significant. Finally, the only significant environmental variable was O3.
When modeling COPD mortality, no covariate was universal across all quintiles,
however percentage single parent households, percentage of people aged 16-64 years
with physical disability, and percentage Black or African American was found across
four of the quintile groups. Among the environmental pollutant data, none were
significant for COPD mortality alone, however ozone was the only environmental
pollutant that showed significance in a combination analysis of cardiovascular diseases,
cancers, and COPD. Thus, it will be pertinent to test the significance of PAHs with the
proposed study.
Given the evidence mentioned above for inclusion of such covariates, Table 1
provides a summary of the covariates that were tested in the COPD Poisson model.
Finally, it should be noted that a variety of soil, water, and other ambient air pollution
covariates could be included that have not been expounded upon or discussed for
consideration into the model. However, since the goal of this research was to first test the
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strength of PAHs in a regression of COPD/lung cancer mortalities, pursuit of additional
air, water, and soil data sources could be considered by follow-up studies, especially
considering the uniqueness and expenditure of resources that acquiring this type of data
entails.
Lung Cancer Model Covariates
Many of the proposed covariates for COPD will be utilized in the lung cancer
model as well, especially considering the framework provided by Chan et al. (2015).
However, to explore whether unique covariates for lung cancer mortality exist, a review
of the lung cancer mortality literature among population-based studies was carried out.
The first item to consider in this review was what Chan et al. (2015) identified in their
regression parameters when assessing cancer mortality in the U.S. The only covariate
with significant results for all of the quintiles was percentage of people aged 16-64 years
with physical disability. One additional covariate had significance among four of the
quintiles – percentage Hispanic or Latino. Ozone was the only environmental pollutant
that showed significance in a combination analysis of cardiovascular diseases, cancers,
and COPD; as well as cardiovascular diseases, cancers, and reductions in life expectancy.
A follow-up study assessing the ABO phenotypes and inflammation-related
predictors of lung cancer mortality was carried out by Suadicani, Hein, & Gyntelberg
(2007). Among the various phenotypes assessed, significant predictors included tobacco
consumption, high salt intake, long-term occupational dust exposure, high fat intake, and
consumption of alcohol. Thus, dietary factors and inflammation-related factors like
hypertension as was discussed by Chan et al. (2015), should be considered with the lung
cancer model as well. As phenotype is mentioned at this juncture, it is important to note
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that genetic covariates to be tested in the proposed regression study are outside of the
scope of this analysis, due again to its ecological design without the benefit of individual
medical records.
Future directions in lung cancer epidemiology were addressed by Alberg, Brock,
& Samet (2005). They focused on the pandemic of lung cancer over the 20th century
largely in part due to smoking and admit that smoking rates are in decline and thus lung
cancer should be in decline over the next decade and will begin to level off around 2030.
They admit that unless greater reductions are made in smoking prevalence however, the
burden of lung cancer will continue to persist. Thus, it is imperative to assess the
contribution that both smoking and air pollution have on lung cancer mortality.
Socio-economic predictors of lung cancer mortality were tested by Mazza et al.
(1999). Low income and rural environment were both significant predictors identified in
their double cohort study when compared to subjects living in an industrial town. They
conclude that smoking, alcohol consumption, and poor living conditions can increase
cancer mortality even when other protective environmental conditions like rural
Mediterranean life are present.
Kanarek, Fitzek, Su, Brower, & Jia (2008) explored the ecological predictors of
lung cancer mortality at the county level by use of decision tree analysis with the
intended benefit of targeting public health practitioners. They determined significant
predictors included smoking, prior coronary heart disease mortality, poverty, and
National Air Toxics Assessment excess cancer deaths estimates provided by the EPA in
the NATA datasets.
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Supporting the inclusion of secondhand tobacco smoke into a risk model includes
the work of Burnett et al. (2014). They created a global burden of disease risk function
attributable to fine particulate matter (PM2.5). The significant covariates determined in
their analysis included ambient air pollution, secondhand smoke, household solid cooking
fuel, and active smoking. The population attributable fractions for ambient air pollution
exposure for COPD and lung cancer was < 1 to 21 and < 1 to 25 respectively.
Methodology Summary
Goal: To assess annual PAH exposure concentrations in South Carolina and to
what extent they contribute to mortality from COPD and lung cancer.
Objective: Investigate the strength of association between NATA-derived census
tract PAH exposure concentrations and deaths from COPD and lung cancer using Poisson
regression modeling.
Null hypothesis: There is no significant association between NATA-derived PAH
exposure concentrations and mortality from COPD and lung cancer at the census tract
level.
Alternative Hypothesis: There is a significant association between NATA-derived
PAH exposure concentrations and mortality from COPD and lung cancer at the census
tract level.

Results
The analysis completed for chapter three focused on census tract comparisons of
COPD and lung cancer deaths in South Carolina. Census tract death counts of COPD and
lung cancer were utilized as the dependent variables in respective Poisson regression

89

models while adjusting for known confounders. Four models were carried out for COPD
and lung cancer deaths each. Eight total analyses were completed using five-year death
aggregates for both diseases for the following year ranges: 2002-2006, 2004-2008, 20062010, and 2010-2014. It is important to reiterate that 2011 NATA data was assessed
using the 2010-2014 models and no significant differences were observed among the
PAH associations with the outcome variables, and the results have not been included.
Again, the 2014 NATA data used for the 2010-2014 models and the results are included
below.
The primary datasets utilized in the analysis included vital statistics mortality data
from DHEC PHSIS (as described above), EPA’s NATA data for years 2002, 2005, and
2014, U.S. Census data for 2000 and 2010, Robert Wood John Foundation’s County
Health Rankings (CHR) 2010, CDC’s Community Health Status Indicators (CHSI) 2010,
and NOAA’s Annual Climate Normals from 1981 to 2010. Additionally, water quality
data for a PAH proxy (benzoapyrene- BaP) was provided by DHEC’s Drinking Water
Compliance Monitoring Program for 2002 to 2017. However, no data was generated for
these years as BaP concentrations have never been detected by the program’s monitoring
thresholds. Covariates tested in the model are summarized in Table 3.1 according to their
data source, spatiality (census tract or county), and temporality (years available).
EPA NATA data was utilized in each model for the nearest year available. Thus,
model one (2002-2006) utilized 2002 NATA data, models two and three (2004-2008 and
2006-2010) used the 2005 NATA, and model four (2010-2014) used the 2014 NATA. All
NATA data were available at the census tract level. 2000 U.S. Census covariates were
utilized for the first three models (2002-2006, 2004-2008, and 2006-2010) and 2010
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Census covariates were utilized for model four (2010-2014). All Census data were
available at the census tract level. County Health Rankings and Community Health Status
Indicators were available for only as early as 2010 and only as low as the county level.
Thus, their respective county-level covariates were utilized for all models. Original
sources and documentation for CHR and CHSI have been described elsewhere (Centers
for Disease Control and Prevention, 2010; County Health Rankings, 2018)
NOAA Climate Normals were utilized for their summary of 30 year aggregates of
heating and cooling days. Heating and cooling days were averaged over this period and
included as an annual average in each of the models. NOAA provided Climate Normals
at the county level which were applied to each census tract in the merged dataset for the
respective county they reside in. A small number of counties did not have Climate
Normals data. Thus, cities with available Climate Normals were utilized as a county
proxy for the respective census tracts in the merged dataset.
Each dataset was provided in an original CSV file. They were cleaned for missing
variables, merged, and the rest of the analysis was completed using SAS 9.4. Missing
deaths in the vital statistics dataset were actual zeroes and not missing. Thus, the dataset
was adjusted accordingly. The overall sample sizes for models one through three were
874 census tracts, and model four had a sample size of 1,103 census tracts. Average
counts for lung cancer and COPD deaths at the census track ranged from 12.78 to 13.37
and 9.8 to 11.73, respectively. It is important to note that average lung cancer deaths at
the census tract level decreased from 2002 to 2014, however average COPD deaths
increased during this same time period. A summary of the descriptive statistics of all
covariates used in each model is included in Appendix B (Table B.1-B.4).
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Model 1: Regression of COPD and Lung Cancer Deaths (2002-2006)
Model one consisted of two analyses – a Poisson regression each for COPD
deaths (Model 1.a) and lung cancer deaths (Model 1.b). All covariates included in the
models were proportions i.e. percentage of females per census tract, percentage of
African Americans per census tract, percentage of smokers per county, average number
of heating days per county, etc. An offset statement was used in the model which
transformed death counts (dependent variable) into rates. This was carried out since the
dependent variables were originally available in five-year aggregates. Census tract
population counts were log transformed and then included as the new variable for the
offset. The models carried out were multi-level regressions as they included both census
tract and county-based covariates.
The number of observations read in model one were 602. Statistical significance
was defined as those estimates with a p-value < 0.05. In Model 1.a, covariates identified
as those with statistically significant estimates included Percent Hispanic (p= 0.0408),
Median Household Income (p= 0.0482), Percent with Education of Some High School or
Less (p<0.0001), Adults 65 and Over (p<0.0001), Percent Female (p<0.0001), and PAHs
(p= 0.0048). All statistically significant covariates had point estimates in the positive
direction (with the exception of Percent Hispanic β= -0.0264) indicating a positive
correlation with COPD deaths. It is important to note that Smoking was not statistically
significant (p= 0.8542). A summary of the analysis of the maximum likelihood parameter
estimates from the Poisson regression can be found in Table 3.2.
In model 1.b, statistically significant covariates identified were Construction
Occupation Prevalence (p= 0.0279), Percent with Education of some High School or Less
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(p= 0.0038), Percent Adults 65 and Over (p<0.0001), Percent Female (p= 0.0269), and
Number of Heating Days (p= 0.0377). It is important to note that Smoking (p= 0.0624)
and PAHs were not statistically significant (p= 0.0624, p=0.1074, respectively) for lung
cancer deaths in model 1.b. Table 3.3 provides a summary of the maximum likelihood
parameter estimates.
Model 2: Regression of COPD and Lung Cancer Deaths (2004-2008)
The methodology utilized in model one was kept the same for models two
through four. 874 observations were read and 602 observations were used in model two.
Statistically significant covariates were the same as in model 1.a (COPD deaths) with the
addition of Percent African American (p=0.0216) and Construction Occupation
Prevalence (p= 0.0285). The point estimates for the significant racial covariates however
were negative (β= -0.0323 and -0.0268, respectively) indicating a negative correlation or
protective effect on COPD deaths. All other covariates were positive, indicating a nonprotective effect on COPD deaths. Again, PAHs were statistically significant (p= 0.0001)
with an estimate in the positive direction (β= 0.1648). It is important to note there was no
significance again with Smoking in model 2.a.
Statistically significant results for model 2.b (Lung cancer deaths) were the same
as in model 1.b with the addition of Hispanic composition (p= 0.032) and Percent Poverty
(p= 0.0165). Hispanic composition and Percent Poverty had negative point estimates
(β= -0.0225 and -0.0093, respectively) indicating a protective effect on lung cancer
deaths. All other covariates had positive point estimates indicating a non-protective effect
on lung cancer deaths. Again, PAHs and smoking were not statistically significant
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(p= 0.2129 and 0.1776). The results of the regression analysis for models 2.a and 2.b can
be located in Appendix B (Tables B.5 and B.6).
Model 3: Regression of COPD and Lung Cancer Deaths (2006-2010)
874 observations were read and 602 were used in model three. Model 3.a (COPD
deaths) resulted in statistically significant covariates that remained the same with model
2.a with the exception of the removal of Percent African American (p= 0.1884). PAHs
remained significant with a p-value < 0.0001 and a positive point estimate (β= 0.1941).
Again, statistical significance was not found with Smoking.
In model 3.b (Lung cancer deaths), statistically significant covariates remained
the same as in model 2.b with the exception of the removal of Percent Female (p=
0.0714) and the addition of Smoking (p= 0.0433). Again, PAHs were not statistically
significant (p= 0.7776) with lung cancer deaths. The results of the regression analysis for
models 3.a and 3.b can be located in Appendix B (Tables B.7 and B.8).
Model 4: Regression of COPD and Lung Cancer Deaths (2010-2014)
The number of observations read and used in model four were 1,104 and 1,081,
respectively. Model 4.a (COPD deaths) resulted in statistically significant covariates that
remained the same as in model 3.a, with the addition of Percent Caucasian (p= 0.0463),
Smoking (p= <0.0001), and Number of Heating Days (p= 0.0028). Hispanic composition
was not statistically significant (p= 0.0545). Percent Caucasian, Smoking, and Number of
Heating Days all had positive point estimates (β= 0.0097, 2.5644, and 0.0039,
respectively). PAHs remained significant (p< 0.0094) with a positive point estimate (β=
0. 0.2342).

94

For model 4.b, statistically significant covariates remained the same with the
exception of the removal of Percent Hispanic (p= 0.0918), and the addition of Percent
Caucasian (p= 0.0068) and Percent Female (p= 0.0004). The point estimates for Percent
Caucasian and Percent Female were both positive (β= 0.0115 and 0.0114, respectively),
indicating a positive correlation with a non-protective effect. The results of the regression
analysis for models 4.a and 4.b can be located in Appendix B (Tables B.9 and B.10).
Finally, Table 3.4 provides a summary of the salient findings from each model for
PAHs. It is important to note that obesity, hypertension, and low physical activity
compositions from CHSI were not statistically significant covariates in any of the
models. Thus, they were removed from the model statements as they did not add any
significance, and are not specified in the tables below.
Application of Model Four to Charleston, SC
To explore the significance of the previous models, model four was applied at a
smaller geographic level to Charleston County. The merged dataset for model four was
stratified at the county-level and selected by Charleston. A new dataset was created and
run using the same covariates as discussed above. Results generated by the model were
unreliable. County-level covariates were kept constant during the analysis as they each
had only one value. Therefore, an application at a large metropolitan level to test the
models’ utility with an area including more than one county is a logical next step to
study. The next chapter will explore this study objective.
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Discussion
The primary research question investigated in this study was whether PAHs were
significantly associated with COPD and/or lung cancer mortality. The rationale for a
mortality investigation from air pollution is supported by works such as (Elliott et al.,
2007; Romieu et al., 2012; Yorifuji et al., 2013), etc. Additionally, modeling hazardous
air pollution exposures and assessing epidemiological outcomes is also documented in
the literature (Bentayeb et al., 2015; Carey et al., 2013; Thurston et al., 2016). Finally, the
biological mechanism described by (Yang et al., 2017) provides a reliable explanation of
the pathogenesis between PAH exposure and COPD occurrence.
Overall, the findings from models one through four support the alternative
hypothesis set forth in this chapter; there is a statistically significance associated with
PAH exposure and COPD/lung cancer mortality. Specifically, PAH exposures
concentrations were found to be significant with COPD mortality while adjusting for
known confounders; however, they were not significantly associated with lung cancer
mortality. The evidence supporting the significant association of PAH exposure
concentrations with COPD mortality achieved a degree of reliability as it was repeated
across four separate models. Future investigation should be carried out to stratify the
analysis by various demographic variables to test for significance in regards to lung
cancer mortalities i.e. whether PAH associations are observed with lung cancer deaths
among females. This is of interest given the findings of Hwang et al. (2007) among
others. Additional discussion on this is addressed below.
Point estimates for PAHs from each model were exponentiated for interpretation.
Thus, based on the analysis carried out in models one through four, the rate of deaths
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from COPD increased by 14%, 18%, 22%, and 23%, respectively for every log unit
increase in PAH exposure. These findings are generally consistent with several
occupational studies as well as various animal studies assessing chronic PAH exposures
and subsequent mortality (Brown, Bailey, Oliveri, Levin, & Di Giulio, 2016; Miller,
Doust, Cherrie, & Hurley, 2013; Randem et al., 2003) Specifically, Randem et al. (2003)
assessed non-malignant disease mortality associated with asphalt workers. Increased
mortality from respiratory diseases was identified among workers in the study. The
authors concluded there was evidence of a dose-response relationship with both PAH
exposure and bitumen fume as coal tar was identified as the source of PAHs. This
adverse impact on respiratory health supports the conclusion of inhalation as the primary
route of PAH exposure.
Additional covariates of interest that resulted in statistically significant
associations and positive estimates with COPD deaths include education level, age,
gender, and heating days. Percent Caucasian was also positively associated and
statistically significant with COPD deaths in model 4.a. These confounders provide
further evidence for their role in overall environmental epidemiological studies assessing
mortality from various hazards. Specifically, the statistically significant findings
associating Percent Females with COPD mortality is supported by the findings from other
epidemiological studies i.e. (Ben-Zaken Cohen, Paré, Man, & Sin, 2007; and Westney et
al., 2017). In detail, Westney et al. (2017) investigated comorbidity associations with
COPD emergency department visits and found that females were identified with COPDassociated ED visits. Ben-Zaken Cohen et al. (2007) suggests there is a worrying trend
among females with both COPD and lung cancer. They go on to elaborate that annual
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COPD mortality rates increased by 291 percent among U.S. women between 1980 and
2000, in addition to a hospital admission rate increase of 43 percent. This dwarfed the
male rates which were 60 percent and 12 percent, respectively. Thus, further
investigation is warranted to test the significance of PAH exposure and COPD/lung
cancer deaths to assess a potentially disproportionate effect on females.
The significance of heating days as a confounder with both COPD and lung
cancer mortality is important to note. Its rationale for inclusion in the model was based on
the work of Chan, Weinhold, Thomas, Gohlke, & Portier (2015). Specifically, Osman et
al. (2008) report that poorer respiratory health status among COPD patients is associated
with days when heating was not adequately kept in residences. Thus, colder months
demonstrate a seasonal influence on COPD severity. Additionally, there is a potential link
of heating days with increased PAH exposure where the number of days in which heating
is required for residences would be associated with an increased load of combustion of
fossil fuels for heat whether burning a coal stove, electrically derived heat, or combustion
of natural gas. Natural gas combustion and electrically sourced heat are further along the
spectrum of complete combustion in jurisdictions with power and gas grids, which would
emit fewer PAHs into the ambient air. Thus, an environmental explanation such as this
would be more probable in contexts where biomass burning for heating and cooking are
highly utilized (Sana, Somda, Meda, & Bouland, 2018).
Strengths and Limitations
This is the first ecological study of its kind to employ NATA data at the census
tract level to assess state-wide associations of PAHs with respiratory-related mortalities.
The state-wide assessment provided a significant sample size of census-tract observations
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to test the strength of associations among COPD, lung cancer, and PAHs while adjusting
for known confounders. It employed a comprehensive set of confounders to attempt to
eliminate potential bias from known sources. Finally, the biological mechanism
establishing the pathogenesis between PAH exposure and COPD (and lung cancer) is
significantly documented with investigations like Yang et al. (2017). The mortality
models detailed in this study provide additional evidence beyond the association of initial
COPD occurrence, and point to further required research to investigate the increased
burden from COPD mortality.
The limitations of the study include cross-level bias (true with any ecological
investigation), in addition to several covariates that were expected to demonstrate
statistical significance, however they did not (i.e. smoking and primary care provider
rates). Additionally, Percent Poverty had mixed results that showed significance with
three out of the four lung cancer models but insignificance with COPD’s models. Crosslevel bias was inherent in this study due to the availability of covariate data. Thus, a
multi-level model was carried out as certain covariates were only available at the county
level. Additionally, mortality data was provided by DHEC for years 2002-2010 using
2010 census tract delineations. This created over 200 missing data points for deaths
during the merging process with the other datasets, which were created using year 2000
census tracts. Death data for model four did not have this issue as it utilized 2010 census
tracts along with its respective merged covariate datasets. Along with this spatial
limitation, temporality was a limitation as well since a variety of the covariates were only
available at certain years. Thus, covariate rates pertaining to year ranges in each model
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were applied as a single year, if only provided for a single year, e.g. NATA’s modeling
years for PAHs.
Additionally, smoking is a known and robust confounder in most epidemiological
studies. Its application with epidemiological air pollution studies is well documented as
mentioned above. Thus, possible explanations for smoking not demonstrating statistical
significance with COPD deaths in models one through three is a counterintuitive finding
(it was not statistically significant for lung cancer deaths in models 1.b and 2.b). It is
important to note the year of smoking’s covariate data source. County Health Ranking’s
smoking prevalence estimates were aggregated using data from the Behavioral Risk
Factor Surveillance System (BRFSS) (County Health Rankings, 2018). The earliest year
this data is available in the County Health Rankings data portal is 2010. Thus, a possible
explanation for smoking’s non-statistical significance for COPD deaths in models one
through three is the length of time in which the covariate was modeled and then which
year range the model was applied. Aggregates for BRFSS smoking were acquired prior to
2010 to generate a valid estimate at the county level, however there is an element of
cross-level bias here due to the availability of the data and the extent to which it was
applied to earlier models. Additionally, secondhand smoke was not controlled for due to
the unavailability of any census tract or even county-level data during the study periods
of each model. This is a limitation especially in regards to indoor air exposures. Thus,
additional investigation should be carried out with a secondhand smoke exposure
covariate as this data becomes available.
Next, the lag time between exposure and chronic disease mortality is lengthy,
where utilizing a single year estimate for PAH concentrations would be somewhat
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erroneous to associate with deaths in the same year, as it takes years/decades for chronic
exposure to have an adverse effect on health. This type of attributable mortality approach
however is not without precedence in epidemiological assessments. The Smoking
Attributable Morbidity Mortality and Economic Costs (SAMMEC) modeling developed
by the CDC used this type of single year of smoking prevalence approach to generate
mortality estimates for the same year (Centers for Disease Control and Prevention, 2009).
Additionally, as smoking initiates most often during teen years, individuals are exposed
to PAHs beginning in their early years as well. Since COPD and lung cancer mortality
were highly associated with Percent Population 65 years and above, these estimates were
most likely originated in the older age groups. Thus, the association was modeled not
based on individual dose and response, but with the PAH levels (much like smoking
prevalence) and its correlation with mortality rates. This explanation does not completely
satisfy those investigating an exact dose and response relationship between PAHs and
respiratory-related mortality however. Thus, additional investigation using a protracted
longitudinal study design is warranted to assess mortality impacts based on dosage.
Finally, a shortened study period between exposure and adverse respiratory
outcomes would provide for less variability with something like a morbidity study
design, i.e. regressing hospitalizations from acute exacerbated COPD with NATAderived exposure concentrations of PAHs at the census tract level. This type of study
would be a logical area to investigate to further validate the current study’s findings.
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Table 3.1 Covariate summary for South Carolina Poisson models.
Name

Source

Spatiality

Temporality

Age

Census/ACS

Census Tract

2000 & 2010

Race

Census/ACS

Census Tract

2001 & 2010

Sex

Census/ACS

Census Tract

2002 & 2010

Median HH Income

Census/ACS

Census Tract

2003 & 2010

Education

Census/ACS

Census Tract

2004 & 2010

Poverty

Census/ACS

Census Tract

2005 & 2010

Occupation by Industry

Census/ACS

Census Tract

2000 & 2010

PAHs

EPA

Census Tract

2002, 2005, &
2011

Lung Cancer Deaths

Vital Stats

Census Tract

2002-2014

COPD Deaths

Vital Stats

Census Tract

2002-2014

Total Heating Days

NOAA

County

1981-2010

Total Cooling Days

NOAA

County

1981-2010

Hypertension

CHSI

County

2010

No Exercise

CHSI

County

2010

Smoking

RWJ

County

2010

Obesity

RWJ

County

2010

Primary Care

RWJ

County

2010

RWJ

County

2010

Physicians
Binge Drinking
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Table 3.2 Model 1.a: Point estimates and p-values, South Carolina COPD deaths (20022006).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Intercept

-7.5582

1.5529

-10.601

-4.514

Caucasian

-0.0114

0.0136

-0.038

0.0153 0.7

0.4026

Hispanic

-0.0264

0.0129

-0.0516

-0.001

4.18

0.0408

African_American

-0.0203

0.0135

-0.0467

0.0061 2.26

0.1325

Percent_Poverty

0.0038

0.0045

-0.005

0.0127 0.72

0.3948

MedianHHIncome

0

0

0

0

3.9

0.0482

Construction_Occu 0.0087

0.0068

-0.0046

0.022

1.65

0.1995

SomeHSorLess

0.0004

0.0001

0.0003

0.0006 35.2

<.0001

Adults65nOver

0.045

0.0046

0.036

0.054

95.51

<.0001

Female

0.0448

0.0114

0.0224

0.0672 15.37

<.0001

logPAHPOM

0.1352

0.0479

0.0413

0.2292 7.97

0.0048

Smoke

-0.1565

0.8511

-1.8247

1.5118 0.03

0.8542

LogPCP

-0.0088

0.058

-0.1225

0.1049 0.02

0.8791

Heat_Days

0.0036

0.0018

0

0.0072 3.83

0.0505

BingeDrink

1.5348

0.9682

-0.3629

3.4325 2.51

0.1129

Scale

1.6112

0

1.6112

1.6112

Degrees of freedom (df) for all covariates = 1. Scale df = 0.
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23.69

Pr > ChiSq

<.0001

Table 3.3 Model 1.b: Point estimates and p-values, South Carolina lung cancer deaths
(2002-2006).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-6.4844

1.2218

-8.8791 -4.0898 28.17

<.0001

Caucasian

-0.0094

0.0109

-0.0308 0.012

0.74

0.3889

Hispanic

-0.0189

0.0101

-0.0388 0.001

3.47

0.0625

African_American

-0.011

0.0108

-0.0322 0.0101

1.04

0.3074

Percent_Poverty

-0.0045

0.0037

-0.0118 0.0028

1.44

0.2304

MedianHHIncome

0

0

0

0

3.43

0.064

Construction_Occu 0.0119

0.0054

0.0013

0.0225

4.83

0.0279

SomeHSorLess

0.0002

0.0001

0.0001

0.0003

8.37

0.0038

Adults65nOver

0.0424

0.0037

0.0351

0.0498

128.58

<.0001

Female

0.0184

0.0083

0.0021

0.0347

4.9

0.0269

logPAHPOM

0.064

0.0389

-0.0122 0.1403

2.71

0.0997

Smoke

1.2629

0.6776

-0.0652 2.591

3.47

0.0624

LogPCP

0.0103

0.0463

-0.0804 0.101

0.05

0.824

Heat_Days

0.0031

0.0015

0.0002

0.0059

4.32

0.0377

BingeDrink

0.8371

0.7681

-0.6685 2.3426

1.19

0.2758

Scale

1.5251

0

1.5251

1.5251

Degrees of freedom (df) for all covariates = 1. Scale df = 0.

104

Table 3.4 Point estimates and p-values for overall PAHs in models 1-4, South Carolina
(2002-2014).
Model

Point Estimate

P-Value

Model 1.a

0.1352

0.0048

0.064

0.0997

0.1648

0.0001

0.0454

0.2223

0.1998

<.0001

0.0104

0.7776

0.2342

0.0094

-0.0388

0.6204

COPD Deaths 2002-2006
Model 1.b
Lung Cancer Deaths 2002-2006
Model 2.a
COPD Deaths 2004-2008
Model 2.b
Lung Cancer Deaths 2004-2008
Model 3.a
COPD Deaths 2006-2010
Model 3.b
Lung Cancer Deaths 2006-2010
Model 4.a
COPD Deaths 2010-2014
Model 4.b
Lung Cancer Deaths 2010-2014
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Figure 3.1 South Carolina county names and locations.
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Figure 3.2 PAH total exposure concentrations by census tract in South Carolina
(2002).
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Figure 3.3 PAH total exposure concentrations by census tract in South Carolina
(2005).
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Figure 3.4 PAH total exposure concentrations by census tract in South Carolina
(2014).
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CHAPTER 4
ESTIMATING THE STRENGTH OF ASSOCIATION AMONG COPD
AND LUNG CANCER DEATHS ATTRIBUTABLE TO PAHS IN NEW
YORK CITY
Overview
Chapter four was an application of the models derived in chapter three’s
investigation in the context of New York City. The five counties of NYC included in the
analysis were Bronx, Kings, New York, Queens, and Richmond counties. The intent for
this application was an attempt at predictive analysis to demonstrate the health effects of
pollution in a population-dense context in regards to PAH load from multiple point and
non-point sources. The connection of this application was to estimate the outcomes of
pollution increases as to what may be anticipated for the port expansion in Charleston.
The burden of COPD and lung cancer in New York City is significant. The
prevalence of COPD in the City was estimated at 5.5 percent according to the state’s
2014 BRFSS surveillance (New York State Department of Health, 2014). Mortality from
COPD in New York City was identified to be 20.0 per 100,000 population in 2014 (New
York City Department of Health Vital Statistics, 2018). The average annual incidence of
lung cancer cases between 2010-2014 for men and women was 60.3 per 100,000 males
and 57.2 per 100,000 females respectively. Mortality rates for lung cancer were 41.5 per
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100,000 males and 25.0 per 100,000 females for the same time period (New York State
Department of Health, 2018)
Methods
The same data sources for covariates and PAHs were applied in chapter four.
Mortality data was acquired from the New York City Department of Health Vital
Statistics Office and used as the dependent variable.
Census tract mortality datasets from COPD and lung cancer were acquired in five
year aggregates from NYC Vital Statistics for the following yearly ranges: 2002-2006,
2004-2008, 2006-2010, and 2010-2014. Modeling using these year ranges with
concentrations for census tract PAHs derived in chapter three were utilized to regress
with the above mortality data. Again, PAH estimates at the census tract level were
acquired from EPA’s website for NATA estimates for the years 2002, 2005, and 2014.
Methodology Summary
Goal: To apply the model derived in chapter three to assess annual PAH exposure
concentrations in New York City and to what extent they contribute to mortality from
COPD and lung cancer.
Objective 1: Investigate the strength of association between NATA-derived
census tract PAH exposure concentrations and deaths from COPD
Objective 2: Investigate the strength of association between NATA-derived
census tract PAH exposure concentrations and deaths from COPD
Null hypothesis: There is no significant association between NATA-derived PAH
exposure concentrations and mortality from COPD and lung cancer at the census tract
level in New York City.
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Alternative Hypothesis: There is a significant association between NATA-derived
PAH exposure concentrations and mortality from COPD and lung cancer at the census
tract level in New York City.

Results
Chapter four’s analysis mimicked that of chapter three with the exception of a different
study jurisdiction. Five counties pertaining to greater New York City were included in the
study area. These counties were selected based on the New York City Department of
Health’s regulation authority including where their public health surveillance is
monitored. Thus, the counties included in the analysis were those identified in the
methods (Figure 4.1).
The primary datasets utilized in the analysis were the same as in chapter three
with the exception of the mortality data. As was addressed in the methods, NYC Vital
Statistics provided this data in the same year ranges as chapter three (2002-2006, 20042008, 2006-2010, and 2010-2014).
NOAA Climate Normals were applied for each county where available. Data for
heating and cooling days from New York County were utilized for Kings and Richmond
Counties since this was the next closest location with available data. Bronx and Queens
Counties had their own respective data for heating and cooling days.
The same covariates tested in chapter three’s models were utilized in chapter four
and are summarized in Table 3.1 according to their source, spatiality, and temporality.
Four models were generated for each respective iteration of the five-year mortality
aggregates of COPD and lung cancer. SAS 9.4 was used to run the analysis including
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merging all datasets. The overall sample size for models one and two was 2,217 census
tracts. Model three had a sample size of 2,218 and model four had a sample size of 2,168
census tracts.
A significant number of missing values for COPD and lung cancer deaths were
observed due to the suppression threshold delineated by NYC Vital Statistics (deaths
suppressed if n < 5). Thus, death counts were set equal to 4 (5/√2) if missing, to account
for suppression. This was an ad-hoc single data imputation adjustment carried out to
accommodate the issue of left censored data due to the lower limit detection that NYC
Vital Statistics uses for mortality data suppression in their census tract datasets.
Descriptive statistics for each model are included in Appendix C (Tables C.1-C.4).
Statistical significance was defined as those estimates with a p-value < 0.05.
Model 1: Regression of COPD and Lung Cancer Deaths (2002-2006)
Model one consisted of two analyses – a Poisson regression each for COPD
deaths (Model 1.a) and lung cancer deaths (Model 1.b). All model statements from
chapter three were repeated for chapter four’s models, i.e. the offset was set as the log of
the census tract population.
The number of observations used and read in model one were 2,217 and 2,159,
respectively. Six statistically significant covariates were identified in the analysis for
model 1.a: Percent Caucasian (p=0.0242), Percent African American (p<0.0001), Median
Household Income (p<0.0001), Construction Occupation Prevalence (p= 0.001), Percent
with Education of Some High School (p=0.0049), Percent Adults 65 and over
(p<0.0001), and Percent Male (p<0.0001). All significant covariates had point estimates
that were positive, indicating a positive correlation or non-protective effect with COPD
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deaths. PAHs were not statistically significant (p= 0.1549) and had a negative point
estimate (β= -0.0772). A summary of the analysis of the maximum likelihood parameter
estimates from the Poisson regression can be found in Table 4.1.
Nine covariates were statistically significant with lung cancer deaths in model 1.b:
Percent Caucasian (p<0.0001), Percent Hispanic (p<0.0001), Percent African American
(p<0.0001), Construction Occupation Prevalence (p=0.0046), Percent with Education of
Some High School (p=0.0005), Percent Adults 65 and Over (p<0.0001), Percent Male
(p<0.0001), Smoking (p<0.0001), and Number of Cooling Days (p=0.0478). All
significant covariates had point estimates in the positive direction indicating a positive
correlation or non-protective effect on lung cancer deaths, with the exception of Percent
Hispanic (β= -0.0033). PAHs were not statistically significant (p= 0.2741) and had a
positive point estimate (β= 0.0479). A summary of the analysis of the maximum
likelihood parameter estimates can be found in Table 4.2.
Model 2: Regression of COPD and Lung Cancer Deaths (2004-2008)
The methodology for model one was repeated for models two through four. The
number of observations used and read in model two were 2,217 and 2,159, respectively.
The significant covariates identified in model 2.a were: Percent African American
(p<0.0001), Median Household Education (p<0.0001), Construction Occupation
Prevalence (p= 0.0032), Percent with Education of Some High School (p= 0.0055),
Adults 65 and over (p<0.0001), Percent Male (p<0.0001). All significant covariates had
point estimates that were positive, indicating a positive correlation or non-protective
effect with COPD deaths. PAHs were not statistically significant (p= 0.7167) and had a
negative point estimate (β= -0.0209).
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The statistically significant covariates identified in model 2.b were: Percent
Caucasian (p=0.0003), Percent Hispanic (p<0.0001), Percent African American
(p=0.0003), Construction Occupation Prevalence (p= 0.0039), Percent with Education of
Some High School (p<.0001), Adults 65 and Over (p<0.0001), Percent Male (p<0.0001),
PAHs (p=0.0174), Percent Who Smoke (p<0.0001), and Number of Cooling Days
(p=0.0297). All significant covariates had point estimates in the positive direction
indicating a positive correlation or non-protective effect on lung cancer deaths, with the
exception of Percent Hispanic (β= -0.0038). PAHs were statistically significant with a
positive point estimate (β= 0.1135). A summary of the analysis of the maximum
likelihood parameter estimates for both models can be found in Appendix C (Tables C.5
and C.6).
Model 3: Regression of COPD and Lung Cancer Deaths (2006-2010)
The number of observations used and read in model three were 2,218 and 2,159,
respectively. The statistically significant covariates identified in model 3.a were: Percent
African American (p<0.0001), Median Household Income (p<0.0001), Construction
Occupation Prevalence (p= 0.0043), Percent with Education of Some High School
(p=0.0003), Adults 65 and over (p<0.0001), and Percent Male (p<0.0001). All significant
covariates had point estimates that were positive, indicating a positive correlation or nonprotective effect with COPD deaths. Again, PAHs were not statistically significant
(p=0.5878) and had a negative point estimate (β= -0.0312).
The statistically significant covariates identified in model 3.b were: Percent
Caucasian (p=0.0015), Percent Hispanic (p<0.0001), Construction Occupation
Prevalence (p=0.0002), Percent with Education of Some High School (p=0.0001), Adults
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65 and Over (p<0.0001), Percent Male (p<0.0001), PAHs (p= 0.04), and Smoking
(p<0.0001). All significant covariates had point estimates in the positive direction
indicating a positive correlation or non-protective effect on lung cancer deaths, with the
exception of Percent Hispanic (β= -0.0038). Again, PAHs were significant with a positive
point estimate (β= 0.0972). A summary of the analysis of the maximum likelihood
parameter estimates for both models can be found in Appendix C (Table C.7 and C.8).
Model 4: Regression of COPD and Lung Cancer Deaths (2010-2014)
The numbers of observations read and used in model 4 were 2,129 and 2,107,
respectively. Statistically significant covariates in model 4.a (COPD deaths) were:
Percent Caucasian (p= 0.0250), Percent African American (p<0.0001), Adults 65 and
over (p<0.0001), Percent Male (p<0.0001), and PAHs (p<0.0001). All significant point
estimates were indicated in the positive direction with the exception of PAHs (β= 0.3115).
The statistically significant covariates identified in model 4.b (lung cancer deaths)
were: Percent Caucasian (p <.0001), Percent Hispanic (p<0.0001), Percent African
American (p= 0.0003). Percent Median Household Income (p=0.0032), Construction
Occupation Prevalence (p= 0.0059), Percent with Education of Some High School or less
(p=0.0002), Adults 65 and Over (p<0.0001), Male (p= 0.0486), and Smoking (p=0.0025).
All significant covariates had point estimates in the positive direction indicating a
positive correlation or non-protective effect on lung cancer deaths, with the exception of
Percent Hispanic (β= -0.0035). A summary of the analysis of the maximum likelihood
parameter estimates for both models can be found in Appendix C (Tables C.9 and C.10).
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Finally, Table 4.3 provides a summary of the salient findings from each model for
PAHs. Elaboration on some of the other statistically significant covariates identified in
the analysis is included below.

Discussion
As discussed in chapter three, the evidence for mortality associations with air
pollution is supported by various epidemiological studies. Additionally, utilizing modeled
air pollutant concentrations for health studies has precedence in the epidemiological
literature. Finally, the pathogenic potential of PAHs with COPD and lung cancer is
supported by biological mechanisms such as what was proposed by Yang et al. (2017).
Overall, the findings from models one through four do not support either the null
or alternative hypotheses set forth in this chapter. Specifically, PAH exposure
concentrations were found to be significant with lung cancer mortality (a positive
correlation in models two and three β= 0.1135, 0.0972), while adjusting for known
confounders. Conversely, PAH exposure concentrations were not significantly associated
with COPD mortality in three out of the four models, and were negatively associated with
a statistical significance in model four (p= 0.0007, β= -0.3115), while adjusting for
known confounders. The mixed results generated by comparing the first three models
with model four in either case of lung cancer or COPD mortality gives rise to a degree of
reduced reliability with the overall findings.
The findings from chapter four’s analysis are not consistent with the findings
from chapter three due to the mixed results and negative correlations with both COPD
and lung cancer in each model. Models two and three did however demonstrate statistical
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significance with PAHs and lung cancer deaths. This is inconsistent with the findings
from the lung cancer models in chapter three, however consistent with occupational
studies such as Miller, Doust, Cherrie, & Hurley (2013). These inconsistencies are
possibly related to the change in jurisdiction where the variability of known confounders
modified the effect on mortality, especially among the county-level confounders.
Another explanation for the inconsistent findings is related to the suppression
threshold NYC Vital Statistics applied to their datasets that transforms death counts less
than five into missing values. A large number of missing values can add bias and reduce
representativeness of a sample; where imputation can reduce such effects (Enders, 2010).
Adjustment was made for this in the analysis. It is possible this reduced the amount of
precision and could have yielded different conclusions based on potential other methods
that could have been used (Asselineau, Thiébaut, Perez, Pinganaud, & Chêne, 2007). The
negative correlations identified in model four still suggest however that another issue(s)
was influencing the results.
Figures 4.2, 4.3, and 4.4 depict the total exposure concentrations by census tract
in NYC across three iterations of NATA (2002, 2005, and 2011). As Figure X depicts,
the exposure concentrations in 2011 were significantly reduced compared to the previous
iterations of NATA. It is unclear if this was related to the modeling changes between
2005 and 2011 or if this was related to what was actually occurring in situ. This reduction
in concentrations exhibited by EPA’s modeling was also depicted for South Carolina in
between 2005 and 2011. Findings for COPD deaths were still found to be positively
correlated with statistical significance in South Carolina for 2011 however. This suggests
the likelihood that a smaller geographic jurisdiction such as NYC exhibited exaggerated
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results when compared to the state-wide analysis in chapter three, possibly due to the lack
of variability of the effect of a reduced application of county-level covariates on a smaller
jurisdiction. This, in addition to the smaller PAH concentration estimates provide likely
explanations of these inconsistencies.
Strengths and Limitations
The large sample size of census tracts that make up greater New York City
provided for an increased number of observations compared to the state-based study in
chapter three. By applying a greater number of observations to a smaller geographic area,
the probable interface between a dense population and pollution exposures was increased.
The variability of county-level covariates was greatly reduced compared to chapter three
however, which had 46 separate counties to compare. Chapter four included a total of
five counties with respective county-level covariates exhibiting a much smaller number
of variability in county-level data to be regressed. Again, this may have exaggerated the
effects of the county-level covariates in chapter four’s models.
Additional analyses from both state-wide as well as more localized regions (other
large metropolitan areas) are warranted to further explore the findings from chapters three
and four. If an analysis is attempted on a smaller geographic area, adjusting the model to
account for the county-level covariate variability must be explored with procedures such
as multiple imputation. It is important to note the analysis carried out in chapter three to
apply the fourth model to Charleston County, SC, exhibited similar limitations as NYC.
Unreliable findings were generated due to the invariability of the county-based
covariates. Thus, a state-wide assessment is recommended with the proposed models that
are depicted in chapters three and four.
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Table 4.1 Model 1.a: Point estimates and p-values, NYC COPD deaths (2002-2006).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Intercept

-11.612

2.4234

-16.361

-6.862

Caucasian

0.0026

0.0011

0.0003

0.0048 5.08

0.0242

Hispanic

0.0016

0.001

-0.0003

0.0036 2.67

0.1022

African_American

0.0068

0.0011

0.0048

0.0089 41.4

<.0001

Percent_Poverty

0.0027

0.002

-0.0012

0.0067 1.85

0.1743

MedianHHIncome

0

0

0

0

<.0001

Construction_Occu 0.0132

0.004

0.0054

0.0211 10.86

0.001

SomeHighSchool

0.0088

0.0031

0.0027

0.015

0.0049

Adults65nOver

0.0439

0.0023

0.0395

0.0483 377.61

<.0001

Male

0.0389

0.0043

0.0305

0.0474 81.7

<.0001

logPAHPOM

-0.0772

0.0543

-0.1837

0.0292 2.02

0.1549

Smoke

2.8389

1.641

-0.3773

6.0552 2.99

0.0836

LogPCP

0.0089

0.2881

-0.5558

0.5736 0

0.9754

Cool_Days

0.0115

0.0468

-0.0802

0.1031 0.06

0.806

BingeDrink

-0.4126

3.3351

-6.9493

6.1241 0.02

0.9015

Scale

1.2827

0

1.2827

1.2827

Degrees of freedom (df) for all covariates = 1. Scale df = 0.
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22.96

Pr > ChiSq

31.89

7.93

<.0001

Table 4.2 Model 1.b: Point estimates and p-values, NYC lung cancer deaths (20022006).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-13.2031

1.9439

-17.013

-9.393

46.13

<.0001

Caucasian

0.0038

0.0009

0.002

0.0056 17.55

<.0001

Hispanic

-0.0033

0.0008

-0.0049

-0.001

15.83

<.0001

African_American

0.0038

0.0009

0.0021

0.0055 19.43

<.0001

Percent_Poverty

-0.0007

0.0017

-0.0041

0.0026 0.18

0.6705

MedianHHIncome

0

0

0

0

0.26

0.6104

Construction_Occu 0.0096

0.0034

0.003

0.0163 8.01

0.0046

SomeHighSchool

0.0092

0.0026

0.0041

0.0144 12.28

0.0005

Adults65nOver

0.0336

0.0019

0.0299

0.0373 316.59

<.0001

Male

0.0212

0.0038

0.0137

0.0287 30.73

<.0001

logPAHPOM

0.0479

0.0438

-0.0379

0.1336 1.2

0.2741

Smoke

5.897

1.2795

3.3892

8.4048 21.24

<.0001

LogPCP

0.3339

0.233

-0.1227

0.7905 2.05

0.1518

Cool_Days

0.0741

0.0374

0.0007

0.1474 3.92

0.0478

BingeDrink

-1.6035

2.6979

-6.8914

3.6843 0.35

0.5523

Scale

1.229

0

1.229

1.229

Degrees of freedom (df) for all covariates = 1. Scale df = 0.
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Table 4.3 Point estimates and p-values for overall PAHs across all models, NYC (20022014).
Model

Point Estimate

P-Value

Model 1.a

-0.0772

0.1549

0.0479

0.2741

-0.0209

0.7167

0.1135

0.0174

-0.0312

0.5878

0.0972

0.04

-0.3115

0.0007

-0.0839

0.2899

COPD Deaths 2002-2006
Model 1.b
Lung Cancer Deaths 2002-2006
Model 2.a
COPD Deaths 2004-2008
Model 2.b
Lung Cancer Deaths 2004-2008
Model 3.a
COPD Deaths 2006-2010
Model 3.b
Lung Cancer Deaths 2006-2010
Model 4.a
COPD Deaths 2010-2014
Model 4.b
Lung Cancer Deaths 2010-2014
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Figure 4.1 Greater New York City (NYC) county names and locations.
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Figure 4.2 PAH total exposure concentrations by census tract in New York City (2002).
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Figure 4.3 PAH total exposure concentrations by census tract in New York City (2005).
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Figure 4.4 PAH total exposure concentrations by census tract in New York City (2014).
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CHAPTER 5
CONCLUSIONS
The body of this work sought to investigate the connection between PAHs
sourced from ambient air pollution and adverse respiratory health outcomes, in addition
to testing the strength of such connections through several population-based and
ecological studies. The primary research question tested was whether there was a
statistically significant association between PAHs and adverse respiratory health
outcomes.
In the first chapter, a variety of studies and literature were summarized, specifying
the biological pathway between PAH exposure and subsequent outcomes such as COPD
and lung cancer. The role of the aryl hydrocarbon receptor in oxidative stress in addition
to the impact of chronic inflammation, highlight key elements in the pathogenesis of
COPD and lung cancer. Additionally, PAHs, inflammation, and oxidative stress are
connections made with other chronic diseases as well i.e. CVD (Alshaarawy et al., 2016;
Curfs et al., 2005). Specifically, the work of Yang et al. (2017) was a cogent study
detailing the pathogenesis between PAHs from ambient air pollution and COPD-related
outcomes.
The scope of work in chapter two was based on the urinary metabolites of
respective PAHs collected through NHANES and correlating these biomarkers with
COPD and lung cancer. As a nationally representative sample investigating human
health, NHANES enables extensive investigation into the associations with various health
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outcomes, a host of biomarkers, while including a comprehensive suite of potential
confounders. The findings from chapter two supported the null hypothesis where no
statistical significance was associated with PAH metabolites and COPD among nonsmokers at the national level. The overall model completed in chapter two identified
significant associations with PAHs and COPD prevalence; however when the sample was
stratified by smoking status, no statistical association was identified between the two. The
sample size for the lung cancer cohort was too small to generate any reliable conclusions.
Possible explanations for the lack of significance in the stratified model in spite of the
supporting literature of likely associations, includes the omission of BaP as a primary
PAH, which is not collected via NHANES. Additionally, other biomarkers related to air
pollution i.e. PM2.5 were not explored as potential variables contained within the overall
dataset to further explore the role of air pollution on such health outcomes. Thus,
additional studies using NHANES are warranted to investigate the associations with
PAHs and respiratory health outcomes.
Chapter three was a state-wide population-based ecological study that used the
EPA’s NATA models to investigate the strength of associations with PAH exposure and
COPD and lung cancer mortality in South Carolina. Exploring the public health burden
related to PAHs by investigating a death model was the rationale for first testing whether
a significant environmental health issue exists with PAHs sourced from air pollution in
South Carolina. It is important to note that mortality investigations comprise a significant
portion of public health burden assessments (López-Campos, Tan, & Soriano, 2016).
Overall, the alternative hypothesis was supported by the findings generated by chapter
three’s analysis where a statistically significant and positive association was observed
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between PAH exposure concentrations from air pollution and COPD mortality, while
adjusting for known confounders. All four models generated during the analysis
demonstrated overall reliability as each one identified a positive significance between
PAHs and COPD mortality. No significant associations were observed between PAH
exposures and lung cancer deaths.
Finally, chapter four sought to apply the models developed in the previous chapter
to a smaller jurisdiction to explore their utility at a smaller geographic granularity.
Specifically, chapter four sought to investigate such associations in NYC, a study area
with a dense population and a context known for increased exposures to air pollution
from PAH sources (Jung et al., 2014). The findings generated during the analysis did not
support either the null or alternative hypotheses. Statistically significant associations
were found among PAHs and COPD/lung cancer deaths, however they were not
significant across all models, nor were their point estimates all indicated in the same
direction (positive or negative). The results indicated a degree of unreliability compared
to chapter three’s models when applied to a smaller geographic area. The primary
explanation for this inconsistency was due to the amount of county-level covariates
utilized in the analysis. Since a multi-level Poisson regression procedure was employed
in the models, the number of county-level covariates possibly skewed the results when
fewer counties were included in the study area for the models’ application. Thus,
application of these models is optimum at the state-level and unreliable among large
metropolitan areas that include only a small number of counties. Exploring more granular
geographic estimates for confounders (zip code or census tract), especially for a powerful
confounder such as smoking, would be important advancements in small area estimation
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procedures (McLain et al., 2017) and environmental epidemiological studies to better
assess risk.
Implications and Future Directions
Increased study focus is warranted with PAHs and COPD morbidity and
mortality. The findings from chapter three have significance for South Carolina,
especially as the state considers the future public health implications of growing its
economic initiatives with projects like the expansion of the Port of Charleston and the
development of the new container terminal in the former Navy base of North Charleston.
The increased loads of air pollution projected from this growing transportation hub have
created a significant concern for the surrounding communities near the port (and terminal
facility) as they are added to the various other pollution sources already present in the
area i.e. industrial waste, underground storage tanks, etc. Svendsen et al. (2014) report
that due to the port expansion, traffic increases to the neck communities of the Charleston
peninsula are expected to increase by at least 7,000 diesel truck trips per day, which
equates to a near 70 percent increase from the current daily average. The neck
communities of Charleston will be disproportionately affected by not only the trucks
coming into and out of the area, but also those related to train and container ship
transport. Applying the models generated in chapter three, for every log unit increase
from PAH exposure related to the new transport from the expansion, deaths from COPD
will increase by anywhere between 14 to 24 percent.
Thus, air quality monitoring in Charleston in addition to epidemiological
surveillance are essential elements for vested stakeholders in the port’s expansion.
Furthermore, environmental justice issues for communities like those of the neck area of
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Charleston are undergirded by the findings from this research. Additional policy issues,
mitigation efforts, and air pollution remediation elements are essential considerations for
communities most proximate to PAH pollution sources, especially those with significant
increases expected in the near future. Further study is also necessitated to investigate
morbidity models to assess the acute impact of short-term exposure to PAHs and effects
on COPD and lung cancer hospitalizations, along with other related diseases, i.e CVD,
asthma, etc.
Finally, it was anticipated a significant association among PAH exposure, COPD
mortality, and lung cancer mortality would be observed in NYC. By establishing this
evidence, a framework for environmental justice that has emerged in other urban centers
(Chakraborty, 2009; Gee & Payne-Sturges, 2004; J. Maantay, 2002; J. Maantay, 2007;
Schweitzer & Stephenson, 2007) would be an important exhibit to consider for
application in the neck communities of Charleston as they attempt to mitigate the impacts
from increased loads of air pollution, especially from non-point sources. Thus, additional
investigation is required in both South Carolina and NYC to assess not only the morbidity
impacts from PAHs but smaller area applications of the the mortality models at the
county or city level and their implications for environmental justice.
In conclusion, the evidence demonstrated by the South Carolina models for
COPD mortality establishes a link between PAH exposure and respiratory-related deaths.
This provides additional scientific evidence to the already large body of literature that is
quite contrary to the latest federal administration’s moves to lessen automobile emission
standards. The findings provided above warrant more restriction on emissions regulated
by the EPA, not less. More must be done in South Carolina specifically to prevent,
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mitigate, and remediate the increased loads of pollution from the Charleston expansion,
especially on those populations who are most proximate to the sources as well as those
who have less capacity to protect themselves from ambient air toxins. The economic
gains from Charleston’s growing transportation hub must not come at the cost of the
nearby population. The perpetuation of environmental injustice predicted from the
Charleston port is consistent with numerous other injustices nationally as well as globally
where economic progress overruns public health.
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APPENDIX A – 16 PRIORITY PAHS DEVELOPED BY THE EPA
1.

Acenaphthene

2.

Naphthalene

3.

Fluoranthene

4.

Benz(a)anthracene

5.

Benzo(a)pyrene

6.

Benzo(b)fluoranthene

7

Benzo(k)fluoranthene

8.

Chrysene

9.

Dibenz(a,h)anthracene

10.

Indeno(1,2,3-c,d)pyrene

11.

Acenaphthalene

12.

Fluorene

13.

Phenanthrene

14.

Anthracene

15.

Benzo(ghi)perylene

16.

Pyrene
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APPENDIX B
SUPPLEMENTARY TABLES ASSOCIATED WITH CHAPTER 3
Table B.1. Model 1 descriptive statistics for South Carolina (2002-2006)
Variable

N

N Miss

Minimum Maximum Mean

GEO_id2

874

0

4.5E+10

4.51E+10

4.5E+10

Caucasian

874

0

0.4

99.3

64.37

Hispanic

874

0

0.1

38.3

2.4

African_American

874

0

0

98.8

32.43

Percent_Poverty

871

3

0

100

15.86

MedianHHIncome

874

0

0

200001

36667.29

Construction_Occu 870

4

0

33.1

11.43

Production_Occu

870

4

0

47.6

19.82

SomeHSorLess

874

0

0

3162

719.35

Adults18nOver

874

0

55.6

99.9

75.54

Adults65nOver

874

0

0

41

12.75

Male

874

0

25.2

100

48.58

Female

874

0

0

74.8

51.42

logPAHPOM

858

16

-6.91

-3.63

-5.33

logTotalConc

858

16

-6.73

-3.05

-4.95

Smoke

871

3

0.15

0.33

0.23

160

LogPCP

874

0

-9.21

-6.34

-7.17

LC_Death

619

255

0

121

13.25

COPD_Death

619

255

0

62

9.8

SmokingDeath

619

255

0

104

11.94

161

Table B.2 Model 2 descriptive statistics for South Carolina (2004-2008)
Variable

N

N Miss

Minimum Maximum Mean

GEO_id2

874

0

4.5E+10

4.51E+10

4.5E+10

Caucasian

874

0

0.4

99.3

64.37

Hispanic

874

0

0.1

38.3

2.4

African_American

874

0

0

98.8

32.43

Percent_Poverty

871

3

0

100

15.86

MedianHHIncome

874

0

0

200001

36667.29

Construction_Occu 870

4

0

33.1

11.43

Production_Occu

870

4

0

47.6

19.82

SomeHSorLess

874

0

0

3162

719.35

Adults18nOver

874

0

55.6

99.9

75.54

Adults65nOver

874

0

0

41

12.75

Male

874

0

25.2

100

48.58

Female

874

0

0

74.8

51.42

logPAHPOM

858

16

-7.03

-3.07

-5.45

logTotalConc

858

16

-6.87

-3.12

-5.04

Smoke

871

3

0.15

0.33

0.23

LogPCP

874

0

-9.21

-6.34

-7.17

LC_Death

619

255

0

125

13.37

COPD_Death

619

255

0

62

10.19

SmokingDeath

619

255

0

201

23.05

162

Table B.3 Model 3 descriptive statistics for South Carolina (2006-2010)
Variable

N

N Miss

Minimum Maximum Mean

GEO_id2

874

0

4.5E+10

4.51E+10

4.5E+10

Caucasian

874

0

0.4

99.3

64.37

Hispanic

874

0

0.1

38.3

2.4

African_American

874

0

0

98.8

32.43

Percent_Poverty

871

3

0

100

15.86

MedianHHIncome

874

0

0

200001

36667.29

Construction_Occu 870

4

0

33.1

11.43

Production_Occu

870

4

0

47.6

19.82

SomeHSorLess

874

0

0

3162

719.35

Adults18nOver

874

0

55.6

99.9

75.54

Adults65nOver

874

0

0

41

12.75

Male

874

0

25.2

100

48.58

Female

874

0

0

74.8

51.42

logPAHPOM

858

16

-7.03

-3.07

-5.45

logTotalConc

858

16

-6.87

-3.12

-5.04

Smoke

871

3

0.15

0.33

0.23

LogPCP

874

0

-9.21

-6.34

-7.17

LC_Death

619

255

0

97

13.35

COPD_Death

619

255

0

62

10.93

SmokingDeath

619

255

0

229

27.94

163

Table B.4 Model 4 descriptive statistics for South Carolina (2010-2014)
Variable

N

N Miss

Minimum Maximum Mean

GEO_id2

1104

0

4.5E+10

4.51E+10

4.5E+10

Caucasian

1089

15

0

100

66.52

Hispanic

1089

15

0

57.6

4.45

African_American

1089

15

0

100

29.1

Percent_Poverty

1087

17

0

100

17.55

MedianHHIncome

1084

20

8828

173636

44903.22

Construction_Occu 1085

19

0

37.1

10.96

Production_Occu

1085

19

0

50.8

15.69

SomeHSorLess

1084

20

9074

173636

45206.03

Adults18nOver

1089

15

45.5

100

76.92

Adults65nOver

1089

15

0

64.2

13.7

Male

1089

15

16.9

100

48.68

Female

1089

15

0

83.1

51.32

logPAHPOM

1092

12

-7.02

-5.24

-6.48

Smoke

1100

4

0.15

0.33

0.23

LogPCP

1103

1

-9.21

-6.34

-7.18

LC_Death

1090

14

0

111

12.78

COPD_Death

1090

14

0

57

11.53

SmokingDeath

1090

14

0

234

25.7
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Table B.5 Model 2.a: Analysis of maximum likelihood estimates South Carolina COPD
deaths (2004-2008).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-6.1183

1.475

-9.0092 -3.2273 17.21

<.0001

Caucasian

-0.0193

0.0127

-0.0442 0.0055

2.33

0.1271

Hispanic

-0.0323

0.0125

-0.0568 -0.0079 6.73

0.0095

African_American

-0.0268

0.0126

-0.0514 -0.0022 4.55

0.0329

Percent_Poverty

-0.0019

0.0045

-0.0108 0.0069

0.18

0.6723

MedianHHIncome

0

0

0

0

4.36

0.0368

Construction_Occu 0.0143

0.0065

0.0015

0.0271

4.8

0.0285

SomeHSorLess

0.0004

0.0001

0.0002

0.0005

26.88

<.0001

Adults65nOver

0.0406

0.0046

0.0316

0.0495

79.05

<.0001

Female

0.0367

0.0109

0.0153

0.058

11.35

0.0008

logPAHPOM

0.1648

0.0434

0.0797

0.25

14.4

0.0001

Smoke

0.6377

0.8234

-0.9761 2.2515

0.6

0.4386

LogPCP

-0.0116

0.0563

-0.1219 0.0988

0.04

0.8371

Heat_Days

0.0032

0.0018

-0.0004 0.0067

3.1

0.0783

BingeDrink

0.8982

0.943

-0.9501 2.7465

0.91

0.3409

Scale

1.6007

0

1.6007

1.6007

Degrees of freedom (df) for all covariates = 1. Scale df = 0.
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Table B.6 Model 2.b: Analysis of maximum likelihood estimates South Carolina lung
cancer deaths (2004-2008).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-6.1872

1.2532

-8.6434 -3.731

24.38

<.0001

Caucasian

-0.0101

0.0111

-0.0317 0.0116

0.83

0.363

Hispanic

-0.0225

0.0105

-0.043

African_American

-0.0109

0.0109

-0.0324 0.0105

Percent_Poverty

-0.0093

0.0039

-0.0169 -0.0017 5.75

0.0165

MedianHHIncome

0

0

0

0

3.03

0.0817

Construction_Occu 0.0151

0.0055

0.0043

0.0259

7.51

0.0061

SomeHSorLess

0.0002

0.0001

0.0001

0.0003

11.92

0.0006

Adults65nOver

0.0373

0.0039

0.0296

0.0449

91.84

<.0001

Female

0.0193

0.0085

0.0026

0.036

5.14

0.0234

logPAHPOM

0.0454

0.0372

-0.0275 0.1183

1.49

0.2223

Smoke

0.9369

0.695

-0.4252 2.299

1.82

0.1776

LogPCP

0.0337

0.0473

-0.0589 0.1264

0.51

0.4754

Heat_Days

0.0034

0.0015

0.0004

0.0063

4.93

0.0264

BingeDrink

0.1542

0.7865

-1.3872 1.6956

0.04

0.8446

Scale

1.5612

0

1.5612

-0.0019 4.6

1.5612

Degrees of freedom (df) for all covariates = 1. Scale df = 0.
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1

0.032
0.3179

Table B.7 Model 3.a: Analysis of maximum likelihood estimates South Carolina COPD
deaths (2006-2010).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-6.4149

1.4415

-9.2403 -3.5895 19.8

<.0001

Caucasian

-0.0086

0.0126

-0.0332 0.0161

0.4973

Hispanic

-0.0244

0.0121

-0.0481 -0.0008 4.1

0.0428

African_American

-0.0164

0.0125

-0.0409 0.008

1.73

0.1884

Percent_Poverty

-0.0045

0.0045

-0.0133 0.0042

1.03

0.3093

MedianHHIncome

0

0

0

0

9.36

0.0022

Construction_Occu 0.0156

0.0063

0.0033

0.028

6.17

0.013

SomeHSorLess

0.0003

0.0001

0.0002

0.0005

22.52

<.0001

Adults65nOver

0.0384

0.0045

0.0296

0.0472

73.27

<.0001

Female

0.0278

0.0102

0.0077

0.0478

7.39

0.0066

logPAHPOM

0.1998

0.0415

0.1185

0.2812

23.18

<.0001

Smoke

1.4951

0.7887

-0.0508 3.041

3.59

0.058

LogPCP

-0.0338

0.0541

-0.1397 0.0722

0.39

0.5325

Heat_Days

0.0018

0.0017

-0.0016 0.0052

1.11

0.2927

BingeDrink

0.5016

0.9096

-1.2813 2.2844

0.3

0.5814

Scale

1.6107

0

1.6107

1.6107

Degrees of freedom (df) for all covariates = 1. Scale df = 0.
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0.46

Table B.8 Model 3.b: Analysis of maximum likelihood estimates South Carolina lung
cancer deaths (2006-2010).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-5.9885

1.2334

-8.4059 -3.5711 23.57

<.0001

Caucasian

-0.0104

0.0109

-0.0318 0.0109

0.92

0.3383

Hispanic

-0.0256

0.0105

-0.0461 -0.0051 6.01

0.0143

African_American

-0.0115

0.0108

-0.0327 0.0096

1.14

0.2862

Percent_Poverty

-0.0097

0.0039

-0.0173 -0.0021 6.22

0.0127

MedianHHIncome

0

0

0

0

4.37

0.0366

Construction_Occu 0.0154

0.0054

0.0047

0.0261

8

0.0047

SomeHSorLess

0.0002

0.0001

0.0001

0.0003

9.85

0.0017

Adults65nOver

0.0338

0.0039

0.0262

0.0415

75.08

<.0001

Female

0.0148

0.0082

-0.0013 0.031

3.25

0.0714

logPAHPOM

0.0104

0.0369

-0.0619 0.0828

0.08

0.7776

Smoke

1.3842

0.685

0.0415

2.7268

4.08

0.0433

LogPCP

0.0315

0.0466

-0.06

0.1229

0.46

0.4999

Heat_Days

0.0023

0.0015

-0.0007 0.0052

2.24

0.1343

BingeDrink

0.0062

0.7764

-1.5155 1.5279

0

0.9936

Scale

1.5499

0

1.5499

1.5499

Degrees of freedom (df) for all covariates = 1. Scale df = 0.
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Table B.9 Model 4.a: Analysis of maximum likelihood estimates South Carolina COPD
deaths (2010-2014).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-6.5958

0.8162

-8.1954 -4.9962 65.31

<.0001

Caucasian

0.0097

0.0049

0.0002

0.0192

3.97

0.0463

Hispanic

-0.0066

0.0034

-0.0134 0.0001

3.70

0.0545

African_American

0.0030

0.0049

-0.0067 0.0126

0.36

0.5467

Percent_Poverty

-0.0029

0.0024

-0.0076 0.0017

1.52

0.2176

MedianHHIncome

-0.0003

0.0001

-0.0005 -0.0002 18.18

<.0001

Construction_Occu 0.0078

0.0032

0.0015

0.0141

5.95

0.0147

SomeHSorLess

0.0003

0.0001

0.0002

0.0005

16.74

<.0001

Adults65nOver

0.0266

0.0021

0.0224

0.0307

160.52

<.0001

Female

0.0155

0.0038

0.0080

0.0230

16.44

<.0001

logPAHPOM

0.2342

0.0902

0.0574

0.4110

6.74

0.0094

Smoke

2.5644

0.5433

1.4994

3.6293

22.27

<.0001

LogPCP

0.0227

0.0366

-0.0490 0.0944

0.39

0.5348

Heat_Days

0.0039

0.0013

0.0013

0.0065

8.93

0.0028

BingeDrink

-0.0834

0.7079

-1.4709 1.3040

0.01

0.9062

Scale

1.6249

0.0000

1.6249

1.6249

Degrees of freedom (df) for all covariates = 1. Scale df = 0.
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Table B.10 Model 4.b: Analysis of maximum likelihood estimates South Carolina lung
cancer deaths (2010-2014).a
Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-8.4356

0.7056

-9.8185 -7.0527 142.93

<.0001

Caucasian

0.0115

0.0042

0.0032

0.0197

7.33

0.0068

Hispanic

-0.0051

0.0030

-0.0110 0.0008

2.84

0.0918

African_American

0.0096

0.0043

0.0012

5.07

0.0244

Percent_Poverty

-0.0052

0.0020

-0.0092 -0.0012 6.50

0.0108

MedianHHIncome

-0.0002

0.0001

-0.0004 -0.0001 11.89

0.0006

Construction_Occu 0.0107

0.0028

0.0053

0.0161

14.99

0.0001

SomeHSorLess

0.0002

0.0001

0.0001

0.0004

11.12

0.0009

Adults65nOver

0.0244

0.0018

0.0209

0.0279

186.58

<.0001

Female

0.0114

0.0032

0.0051

0.0178

12.37

0.0004

logPAHPOM

-0.0388

0.0783

-0.1921 0.1146

0.25

0.6204

Smoke

1.9900

0.4644

1.0798

18.36

<.0001

LogPCP

-0.0228

0.0307

-0.0830 0.0374

0.55

0.4580

Heat_Days

-0.0000

0.0011

-0.0022 0.0022

0.00

0.9945

BingeDrink

0.3505

0.6019

-0.8292 1.5302

0.34

0.5603

Scale

1.4718

0.0000

1.4718

0.0180

2.9001

1.4718

Degrees of freedom (df) for all covariates = 1. Scale df = 0.
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SUPPLEMENTARY TABLES ASSOCIATED WITH CHAPTER 4
Table C.1 Model 1 descriptive statistics for NYC (2002-2006)
Variable

N

N Miss

Minimum Maximum Mean

CT_Population

2217

0

0

24523

3612.214

Caucasian

2193

24

0

100

44.74122

Hispanic

2193

24

0

100

24.99567

African_American

2193

24

0

100

28.15581

Percent_Poverty

2168

49

0

100

20.58861

MedianHHIncome

2217

0

0

188697

40056

Construction_Occu 2159

58

0

100

7.188282

Production_Occu

2159

58

0

100

11.76082

SomeHighSchool

2171

46

0

100

16.77577

Adults65nOver

2193

24

0

90

11.89184

Male

2193

24

20

100

47.92832

Female

2193

24

0

80

52.07187

logPAHPOM

2195

22

-14.8739

-2.44459

-4.60907

logTotalConc

2217

0

-5.47354

-1.98934

-4.22184

Smoke

2217

0

0.15

0.23

0.17171
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a

LogPCP

2217

0

-6.95396

-5.86918

-6.66923

COPD_Death

586

1631

5

45

8.517065

COPD_Death_r

2217

0

4

45

5.193956

LC_Death

1124

1093

5

64

10.17349

LC_Death_r

2217

0

4

64

7.129905

Recoded deaths based on single imputation adjustment =4.
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Table C.2 Model 2 descriptive statistics for NYC (2004-2008)

a

Variable

N

N Miss

Minimum Maximum Mean

CT_Population

2217

0

0

24523

3612.214

Caucasian

2193

24

0

100

44.74122

Hispanic

2193

24

0

100

24.99567

African_American

2193

24

0

100

28.15581

Percent_Poverty

2168

49

0

100

20.58861

MedianHHIncome

2217

0

0

188697

40056

Construction_Occu 2159

58

0

100

7.188282

Production_Occu

2159

58

0

100

11.76082

SomeHighSchool

2171

46

0

100

16.77577

Adults65nOver

2193

24

0

90

11.89184

Male

2193

24

20

100

47.92832

Female

2193

24

0

80

52.07187

logPAHPOM

2193

24

-5.66032

-2.51523

-4.45143

LogTotalConc

2193

24

-4.99537

-2.06524

-4.0717

Smoke

2217

0

0.15

0.23

0.17171

LogPCP

2217

0

-6.95396

-5.86918

-6.66923

COPD_Death

560

1657

5

41

8.351786

COPD_Death_r

2217

0

4

41

5.099233

LC_Death

1083

1134

5

61

10.10526

LC_Death_r

2217

0

4

61

6.982409

Recoded deaths based on single imputation adjustment =4.
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Table C.3 Model 3 descriptive statistics for NYC (2006-2010)

a

Variable

N

N Miss

Minimum Maximum Mean

CT_Population

2217

1

0

24523

3612.214

Caucasian

2193

25

0

100

44.74122

Hispanic

2193

25

0

100

24.99567

African_American

2193

25

0

100

28.15581

Percent_Poverty

2168

50

0

100

20.58861

MedianHHIncome

2217

1

0

188697

40056

Construction_Occu 2159

59

0

100

7.188282

Production_Occu

2159

59

0

100

11.76082

SomeHighSchool

2171

47

0

100

16.77577

Adults65nOver

2193

25

0

90

11.89184

Male

2193

25

20

100

47.92832

Female

2193

25

0

80

52.07187

logPAHPOM

2193

25

-5.66032

-2.51523

-4.45143

LogTotalConc

2193

25

-4.99537

-2.06524

-4.0717

Smoke

2217

1

0.15

0.23

0.17171

LogPCP

2217

1

-6.95396

-5.86918

-6.66923

COPD_Death

563

1655

5

38

8.222025

copd_death_r

2218

0

4

38

5.071686

LC_death

1098

1120

5

67

9.852459

lc_death_r

2218

0

4

67

6.897205

Recoded deaths based on single imputation adjustment =4.
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Table C.4 Model 4 descriptive statistics for NYC (2010-2014)

a

Variable

N

N Miss

Minimum Maximum Mean

CT_Population

2129

0

11.00

26588.00

3839.87

Caucasian

2129

0

0.00

100.00

43.65

Hispanic

2129

0

0.00

96.30

26.62

African_American

2129

0

0.00

96.60

27.15

Percent_Poverty

2114

15

0.00

91.80

18.23

MedianHHIncome

2109

20

8694.00

232768.00

54747.31

Construction_Occu 2111

18

0.00

70.00

7.22

Production_Occu

2111

18

0.00

52.90

9.76

SomeHSorLess

2117

12

0.00

85.90

21.25

Adults65nOver

2129

0

0.00

82.60

78.27

Male

2129

0

26.90

98.60

47.73

Female

2129

0

1.40

73.10

52.27

logPAHPOM

2129

0

-6.60

-5.38

-5.97

Smoke

2129

0

0.15

0.23

0.17

LogPCP

2129

0

-6.95

-5.87

-6.67

COPD_Death

667

1462

5.00

48.00

8.42

copd_death_r

2129

0

4.00

48.00

5.39

LC_death

1139

990

5.00

67.00

9.38

lc_death_r

2129

0

4.00

67.00

6.88

Recoded deaths based on single imputation adjustment =4.

Table C.5 Model 2.a: Analysis of maximum likelihood estimates NYC COPD deaths
(2004-2008).a
175

Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-10.7266

2.4639

-15.555

-5.897

18.95

<.0001

Caucasian

0.0018

0.0011

-0.0004

0.004

2.62

0.1056

Hispanic

0.0006

0.001

-0.0014

0.0025 0.33

0.5639

African_American

0.0063

0.001

0.0043

0.0083 37.11

<.0001

Percent_Poverty

0.002

0.002

-0.0019

0.006

1.02

0.3133

MedianHHIncome

0

0

0

0

26.7

<.0001

Construction_Occu 0.0118

0.004

0.004

0.0196 8.7

0.0032

SomeHighSchool

0.0086

0.0031

0.0025

0.0147 7.71

0.0055

Adults65nOver

0.0431

0.0023

0.0387

0.0475 365.29

<.0001

Male

0.0406

0.0042

0.0324

0.0488 93.14

<.0001

logPAHPOM

-0.0209

0.0576

-0.1337

0.0919 0.13

0.7167

Smoke

1.5991

1.7829

-1.8953

5.0936 0.8

0.3698

LogPCP

-0.158

0.2964

-0.7389

0.4229 0.28

0.594

Cool_Days

-0.0068

0.048

-0.1009

0.0873 0.02

0.887

BingeDrink

0.9566

3.4456

-5.7967

7.71

0.7813

Scale

1.2626

0

1.2626

1.2626

0.08

Degrees of freedom (df) for all covariates = 1. Scale df = 0.

Table C.6 Model 2.b: Analysis of maximum likelihood estimates NYC lung cancer
deaths (2004-2008).a
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Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-13.3468

2.0264

-17.318

-9.375

43.38

<.0001

Caucasian

0.0034

0.0009

0.0015

0.0052 13.11

0.0003

Hispanic

-0.0038

0.0008

-0.0055

-0.002

20.46

<.0001

African_American

0.0032

0.0009

0.0015

0.0049 13.37

0.0003

Percent_Poverty

-0.0009

0.0017

-0.0044

0.0025 0.29

0.5907

MedianHHIncome

0

0

0

0

1.35

0.2454

Construction_Occu 0.01

0.0035

0.0032

0.0168 8.34

0.0039

SomeHighSchool

0.0112

0.0027

0.0059

0.0165 17.43

<.0001

Adults65nOver

0.0323

0.0019

0.0285

0.0361 277.01

<.0001

Male

0.0183

0.0039

0.0106

0.026

<.0001

logPAHPOM

0.1135

0.0478

0.0199

0.2071 5.65

0.0174

Smoke

6.7111

1.4207

3.9266

9.4957 22.31

<.0001

LogPCP

0.4044

0.2445

-0.0748

0.8835 2.74

0.0981

Cool_Days

0.0855

0.0393

0.0084

0.1626 4.73

0.0297

BingeDrink

-2.7958

2.8498

-8.3814

2.7897 0.96

0.3266

Scale

1.2433

0

1.2433

1.2433

21.81

Degrees of freedom (df) for all covariates = 1. Scale df = 0.

Table C.7 Model 3.a: Analysis of maximum likelihood estimates NYC COPD deaths
(2006-2010).a
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Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square
18.25

Pr > ChiSq

Intercept

-10.5153

2.4612

-15.339

-5.691

Caucasian

0.0016

0.0011

-0.0006

0.0038 2.12

0.1458

Hispanic

0.0002

0.001

-0.0017

0.0022 0.05

0.823

African_American

0.0056

0.001

0.0036

0.0076 29.86

<.0001

Percent_Poverty

0.0015

0.002

-0.0025

0.0054 0.55

0.4583

MedianHHIncome

0

0

0

0

<.0001

Construction_Occu 0.0114

0.004

0.0036

0.0192 8.15

0.0043

SomeHighSchool

0.0111

0.0031

0.005

0.0171 12.83

0.0003

Adults65nOver

0.0415

0.0023

0.037

0.046

<.0001

Male

0.0408

0.0042

0.0326

0.0489 96.05

<.0001

logPAHPOM

-0.0312

0.0576

-0.1441

0.0817 0.29

0.5878

Smoke

1.0738

1.7844

-2.4235

4.5711 0.36

0.5473

LogPCP

-0.278

0.296

-0.858

0.3021 0.88

0.3476

Cool_Days

-0.019

0.048

-0.113

0.075

0.16

0.6922

BingeDrink

2.129

3.4424

-4.6181

8.876

0.38

0.5363

Scale

1.2568

0

1.2568

1.2568

26.62

328.43

<.0001

Degrees of freedom (df) for all covariates = 1. Scale df = 0.

Table C.8 Model 3.b: Analysis of maximum likelihood estimates NYC lung cancer
deaths (2006-2010).a
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Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-11.1187

2.0043

-15.047 -7.1904 30.77

<.0001

Caucasian

0.0029

0.0009

0.0011

10.13

0.0015

Hispanic

-0.0038

0.0008

-0.0054 -0.0021 20.39

<.0001

African_American

0.0028

0.0009

0.0011

10.66

0.0011

Percent_Poverty

-0.0014

0.0017

-0.0047 0.002

0.63

0.4278

MedianHHIncome

0

0

0

0

1.45

0.2279

Construction_Occu 0.0128

0.0034

0.0061

0.0195

14.1

0.0002

SomeHighSchool

0.0106

0.0027

0.0054

0.0158

15.97

<.0001

Adults65nOver

0.0339

0.0019

0.0302

0.0376

316.91

<.0001

Male

0.0196

0.0039

0.0119

0.0272

25.17

<.0001

logPAHPOM

0.0972

0.0474

0.0044

0.1901

4.22

0.04

Smoke

5.8436

1.4053

3.0893

8.5979

17.29

<.0001

LogPCP

0.2391

0.2412

-0.2337 0.712

0.98

0.3216

Cool_Days

0.0466

0.0389

-0.0296 0.1228

1.44

0.2304

BingeDrink

-1.0714

2.8143

-6.5873 4.4445

0.14

0.7034

Scale

1.2227

0

1.2227

0.0047

0.0045

1.2227

Degrees of freedom (df) for all covariates = 1. Scale df = 0.

Table C.9 Model 4.a: Analysis of maximum likelihood estimates NYC COPD deaths
(2010-2014).a
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Parameter

Estimate Standard Wald 95%
Error

a

Wald

Confidence

Chi-

Limits

Square

Pr > ChiSq

Intercept

-11.8488

2.1035

-15.971

-7.726

31.73

<.0001

Caucasian

0.0020

0.0009

0.0002

0.0037

5.02

0.0250

Hispanic

-0.0009

0.0008

-0.0025

0.0006

1.44

0.2295

African_American

0.0044

0.0008

0.0028

0.0060

29.34

<.0001

Percent_Poverty

0.0010

0.0014

-0.0017

0.0038

0.55

0.4581

MedianHHIncome

-0.0000

0.0000

-0.0000

0.0000

0.07

0.7877

Construction_Occu 0.0002

0.0026

-0.0050

0.0053

0.00

0.9479

SomeHSorLess

0.0029

0.0016

-0.0002

0.0061

3.44

0.0635

Adults65nOver

0.0398

0.0019

0.0361

0.0435

440.93

<.0001

Male

0.0305

0.0045

0.0216

0.0393

45.19

<.0001

logPAHPOM

-0.3115

0.0916

-0.4910

-0.132

11.57

0.0007

Smoke

1.6030

1.5875

-1.5084

4.7144

1.02

0.3126

LogPCP

-0.1455

0.2637

-0.6624

0.3715

0.30

0.5813

Cool_Days

-0.0003

0.0438

-0.0862

0.0856

0.00

0.9943

BingeDrink

0.0145

2.9458

-5.7591

5.7881

0.00

0.9961

Scale

1.0760

0.0000

1.0760

1.0760

Degrees of freedom (df) for all covariates = 1. Scale df = 0.

Table C.10 Model 4.b: Analysis of maximum likelihood estimates South Carolina lung
cancer deaths (2010-2014).a
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Parameter

Estimat

Standar

Wald 95%

Wald

Pr > ChiS

e

d Error

Confidence

Chi-

q

Limits

Squar
e

Intercept

-8.4716

1.7657

-11.932

-5.0108

23.02

<.0001

Caucasian

0.0029

0.0007

0.0015

0.0044

15.68

<.0001

Hispanic

-0.0035

0.0007

-0.0047

-0.0022

27.68

<.0001

African_American

0.0025

0.0007

0.0011

0.0038

12.94

0.0003

Percent_Poverty

-0.0018

0.0012

-0.0041

0.0006

2.18

0.1398

MedianHHIncome

-0.0000

0.0000

-0.0000

-0.0000

8.71

0.0032

Construction_Occ

0.0061

0.0022

0.0018

0.0105

7.59

0.0059

SomeHSorLess

0.0050

0.0013

0.0024

0.0076

13.76

0.0002

Adults65nOver

0.0365

0.0016

0.0333

0.0396

527.12

<.0001

Male

0.0078

0.0039

0.0000

0.0155

3.89

0.0486

logPAHPOM

-0.0839

0.0793

-0.2394

0.0715

1.12

0.2899

Smoke

4.0288

1.3333

1.4156

6.6419

9.13

0.0025

LogPCP

0.2930

0.2240

-0.1459

0.7320

1.71

0.1907

Cool_Days

0.0251

0.0371

-0.0475

0.0977

0.46

0.4984

BingeDrink

-2.6457

2.4989

-7.5435

2.2520

1.12

0.2897

Scale

1.0212

0.0000

1.0212

1.0212

u
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